

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34919 A1(51) International Patent Classification: **C12N 15/53**,
9/04, C12Q 1/32, 1/54 // (C12N 9/04, C12R 1:01)(71) Applicant (for all designated States except DE): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; 124 Gren-
zacherstrasse, CH-4070 Basel (CH).(21) International Application Number: **PCT/EP01/12148**(72) Inventors: **KRATZSCH, Peter**; Dorfstrasse 5, 82387
Antdorf (DE). **SCHMUCK, Rainer**; Am Klosterwei-
her 7, 83671 Benediktbeuern (DE). **BUNK, Daniela**;
Hofmark 8, 82393 Iffeldorf (DE). **SHAO, Zhixin**;
Westend 43, 82377 Penzberg (DE). **THYM, Detlef**; Adal-
bert-Stifter-Strasse 16, 68259 Mannheim (DE). **KNAPPE,**
Wolfgang-Reinhold; Christoph-Kroewerath-Strasse 116,
67071 Ludwigshafen (DE).

(22) International Filing Date: 20 October 2001 (20.10.2001)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
00123512.6 27 October 2000 (27.10.2000) EP
00127294.7 19 December 2000 (19.12.2000) EP(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: VARIANTS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE DEHYDROGENASE

Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)



(57) Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.

WO 02/34919 A1

WO 02/34919 A1

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declaration under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/34919

PCT/EP01/12148

VARIANTS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE DEHYDROGENASE

The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations
5 of sugar, especially of glucose in a sample.

Two types of PQQ-dependent glucose dehydrogenase (EC 1.1.99.17) have been characterized: One is membrane-bound (m-GDH), the other is soluble (s-GDH). Both types do not share any significant sequence homology (Cleton-Jansen, A. M., et al., Mol Gen Genet 217 (1989) 430-6; Cleton-Jansen, A. M., et al., Antonie Van Leeuwenhoek 56
10 (1989) 73-9; Oubrie, A., et al., Proc Natl Acad Sci U S A 96 (1999) 11787-91). They are also different regarding both their kinetic as well as their immunological properties (Matsushita, K., et al., Bioscience Biotechnology & Biochemistry 59 (1995) 1548-1555).

Quinoproteins use quinone as cofactor to oxidize alcohols, amines and aldoses to their corresponding lactones, aldehydes and aldolic acids (Duine, J. A. Energy generation and the
15 glucose dehydrogenase pathway in *Acinetobacter* in "The Biology of *Acinetobacter*" (1991) 295-312, New York, Plenum Press; Duine, J. A., Eur J Biochem 200 (1991) 271-84, Davidson, V. L. - in "Principles and applications of quinoproteins" (1993) the whole book, New York, Marcel Dekker; Anthony, C., Biochem J 320 (1996) 697-711 ;Anthony, C. and Ghosh, M., Current Science 72 (1997) 716-727; Anthony, C., Biochem Soc Trans 26 (1998)
20 413-7; Anthony, C. and Ghosh, M., Prog Biophys Mol Biol 69 (1998) 1-21). Among quinoproteins, those containing the noncovalently bound cofactor 2,7,9-tricarboxy-1H-pyrrolo [2,3-f]quinoline-4,5-dione (PQQ) constitute the largest sub-group (Duine 1991, supra). All bacterial glucose dehydrogenases known so far belong to this sub-group with PQQ as the prosthetic group (Anthony and Ghosh 1997, supra, Goodwin and Anthony
25 1998, supra).

In bacteria, there are two completely different types of PQQ-dependent glucose dehydrogenases (EC1.1.99.17): the soluble type (s-GDH) and the membrane-bound type

WO 02/34919

PCT/EP01/12148

- 2 -

(m-GDH) (Duine et al., 1982; Matsushita et al., 1989a,b). The m-GDHs are widespread in Gram-negative bacteria, s-GDHs, however, have been found only in the periplasmic space of *Acinetobacter* strains, like *A. calcoaceticus* (Duine, 1991a; Cleton-Jansen et al., 1988; Matsushita and Adachi, 1993) and *A. baumannii* (JP 11243949).

- 5 Through searching sequence databases, two sequences homologous to the full-length *A. calcoaceticus* s-GDH have been identified in *E.coli* K-12 and *Synechocystis* sp.. Additionally, two incomplete sequences homologous to *A. calcoaceticus* s-GDH were also found in the genome of *P.aeruginosa* and *Bordetella pertussis* (Oubrie et al. 1999a), respectively. The deduced amino acid sequences of these four uncharacterized proteins are closely related to
- 10 *A. calcoaceticus* s-GDH with many residues in the putative active site absolutely conserved. These homologous proteins are likely to have a similar structure and to catalyze similar PQQ-dependent reactions (Oubrie et al., 1999a).

- Bacterial s-GDHs and m-GDHs have been found to possess quite different sequences and different substrate specificity. For example, *A. calcoaceticus* contains two different PQQ-
- 15 dependent glucose dehydrogenases, one m-GDH which is active *in vivo*, and the other designated s-GDH for which only *in vitro* activity can be shown. Cleton-Jansen et al., (1988;1989a,b) cloned the genes coding for the two GDH enzymes and determined the DNA sequences of both these GDH genes. There is no obvious homology between m-GDH and s-GDH corroborating the fact that m-GDH and s-GDH represent two completely
- 20 different molecules.

- The gene of s-GDH from *A. calcoaceticus* has been cloned in *E. coli* behind a leader sequence and a strong promoter. After being synthesized in the cell, the s-GDH is translocated through the cytoplasmic membrane into the periplasmic space (Duine, J. A. Energy generation and the glucose dehydrogenase pathway in *Acinetobacter* in "The Biology of *Acinetobacter*" (1991) 295-312, New York, Plenum Press, Matsushita, K. and Adachi, O.
- 25 Bacterial quinoproteins glucose dehydrogenase and alcohol dehydrogenase in "Principles and applications of Quinoproteins" (1993) 47-63, New York, Marcel Dekker). Like the native s-GDH from *A. calcoaceticus*, s-GDH expressed in *E.coli* is also a homodimer, with one PQQ molecule and three calcium ions per monomer (Dokter et al., 1986 supra,1987
- 30 supra1988 supra; Olsthoorn, A. and J. Duine, J. A., Arch Biochem Biophys 336 (1996) 42-8; Oubrie, A., et al., J Mol Biol 289 (1999) 319-33, Oubrie, A., et al., Proc Natl Acad Sci U S A 96 (1999) 11787-91, Oubrie, A., et al., Embo J 18 (1999) 5187-94). s-GDH oxidizes a wide range of mono- and disaccharides to the corresponding ketones which further hydrolyze to

WO 02/34919

PCT/EP01/12148

- 3 -

the aldonic acids, and it is also able to donate electrons to PMS (phenazine metosulfate), DCPIP (2,6-dichlorophenolindophenol), WB (Wurster's blue) and short-chain ubiquinones such as ubiquinone Q1 and ubiquinone Q2 (Matsushita, K., et al., Biochemistry 28 (1989) 6276-80; Matsushita, K., et al., Antonie Van Leeuwenhoek 56
5 (1989) 63-72), several artificial electron acceptors such as N-methylphenazonium methyl sulfate (Olsthoorn, A. J. and Duine, J. A., Arch Biochem Biophys 336 (1996) 42-8 ; Olsthoorn, A. J. and Duine, J. A., Biochemistry 37 (1998) 13854-61) and electroconducting polymers (Ye, L., et al., Anal. Chem. 65 (1993) 238-41).

In view of s-GDH's high specific activity towards glucose (Olsthoorn, A. J. and Duine, J. A.,
10 Arch Biochem Biophys 336 (1996) 42-8) and its broad artificial electron acceptor specificity, the enzyme is well suited for analytical applications, particularly for being used in (bio-)sensor or test strips for glucose determination in diagnostic applications (Kaufmann et al., 1997 supra).

Glucose oxidation can be catalyzed by at least three quite distinct groups of enzymes, i.e.,
15 by NAD-dependent, dye-linked glucose dehydrogenases, by flavoprotein glucose oxidase or by quinoprotein GDHs (Duine 1995). A rather slow autooxidation of reduced s-GDH has been observed, demonstrating that oxygen is a very poor electron acceptor for s-GDH (Olsthoorn and Duine 1996). s-GDH can efficiently donate electrons to PMS, DCPIP, WB and short-chain ubiquinones such as Q1 and Q2, but it can not efficiently donate electrons
20 directly to oxygen.

Traditional test strips and sensors for monitoring glucose level in blood, serum and urine e. g. from diabetic patients use glucose oxidase. However, since glucose oxidase transfers its electrons to oxygen, it is known that oxygen may have a negative impact on glucose measurements which are based on this enzyme. The major advantage of PQQ-dependent
25 glucose dehydrogenases is their independence from oxygen. This important feature is e.g., discussed in US 6,103,509, in which some features of membrane-bound GDH have been investigated.

An important contribution to the field has been the use of s-GDH together with appropriate substrates. Assay methods and test strip devices based on s-GDH are disclosed
30 in detail in US 5,484,708. This patent also contains detailed information on the set-up of assays and the production of s-GDH-based test strips for measurement of glucose. The methods described there as well in the cited documents are herewith included by reference.

WO 02/34919

PCT/EP01/12148

- 4 -

Other patents or applications relating to the field and comprising specific information on various modes of applications for enzymes with glucose dehydrogenase activity are US 5,997,817; US 6,057,120; EP 620 283; and JP 11-243949-A.

5 A commercial system which utilizes s-GDH and an indicator that produces a color change when the reaction occurs (Kaufmann et al. 1997) is the Glucotrend® system distributed by Roche Diagnostics GmbH.

Despite the above discussed important advantages there also is a major inherent problem of s-GDH. s-GDH has rather a broad substrate spectrum as compared to m-GDH. That is, s-GDH oxidizes not only glucose but also several other sugars including maltose, galactose, 10 lactose, mannose, xylose and ribose (Dokter et al. 1986a). The reactivity towards sugars other than glucose may in certain cases impair the accuracy of determining blood glucose levels, in some diabetic patients. In particular patients on peritoneal dialysis treated with icodextrin (a glucose polymer) may contain in their body fluids, e.g., in blood, high levels of other sugars, especially maltose (Wens, R., et al., Perit Dial Int 18 (1998) 603-9).

15 Therefore clinical samples, as e.g. obtained from diabetic patients, especially from patients with renal complications and especially from patients under dialysis may contain significant levels of other sugars, especially maltose. Glucose determinations in samples obtained from such critical patients may be impaired by maltose.

There are scarce reports in the literature on attempts to produce modified PQQ-dependent 20 s-GDHs which exhibit altered substrate specificity. Due to a negative outcome most of these efforts have not been published. Igarashi, S., et al., (1999) report that introducing a point mutation at position Glu277 leads to mutants with altered substrate specificity profile. However, none of these mutants, lead to an at least two-fold increased improved specificity for glucose as e.g., compared to xylose, galactose or maltose.

25 It can be summarized that the attempts known in the art aiming at improvements of properties of s-GDH, especially its specificity towards glucose, have not been successful to the extend required for accurate monitoring of glucose levels in patients having also high levels of sugars other than glucose.

A great demand and clinical need therefore exists for mutant forms of s-GDH which 30 feature an improved specificity for glucose as substrate.

WO 02/34919

PCT/EP01/12148

- 5 -

It was the task of the present invention to provide new mutants or variants of s-GDH with significantly improved substrate specificity for glucose as compared to other selected sugar molecules, e.g., like galactose or maltose.

Surprisingly it has been found that it is possible to significantly improve the substrate specificity of s-GDH for glucose, as compared to other sugars, and to at least partially overcome the above described problems known in the art.

The substrate specificity for glucose as compared to other selected sugar molecules has been significantly improved by providing mutant s-GDH according to the present invention as described herein below and in the appending claims. Due to the improved substrate specificity of the new forms of s-GDH, significant technical progress for glucose determinations in various fields of applications is possible.

Summary of the invention:

It has now surprisingly been found that it is possible to provide s-GDH mutants with improved substrate specificity towards glucose as a substrate as compared to other selected sugars. New s-GDH variants are disclosed which exhibit a significant higher substrate specificity for glucose, especially as compared to maltose.

Also disclosed are mutant s-GDH molecules, which, compared to the wild-type enzyme, exhibit essentially equal specific activity for glucose as substrate but markedly reduced activity for other selected sugar molecules.

Such comparison of a mutant's specific activity for one of the various other substrate molecules is based on and calculated in relation to the original enzymatic activities of a wild-type enzyme, e.g., as isolated from *Acinetobacter calcoaceticus*.

Mutated s-GDH proteins as well as polynucleotide-sequences coding for such proteins exhibiting improved properties, especially increased specificity for glucose are also provided.

s-GDH mutants comprising at least one amino acid substitutions at an amino acid position corresponding to a position of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24) selected from the group consisting of positions 348 and 428 have been

WO 02/34919

PCT/EP01/12148

- 6 -

found to provide for s-GDH enzymes with improved properties, especially with improved specificity for glucose. Variants comprising a substitution at position 348 exhibit a strikingly positive effect on glucose specificity.

The improved s-GDH mutants can be used with great advantage for the specific detection or measurement of glucose in biological samples, especially in tests strip devices or in biosensors.

The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Description of the Figures

Figure 1: Nucleotide (DNA) sequence of the *Acinetobacter calcoaceticus* PQQ dependent soluble glucose dehydrogenase gene and the corresponding amino acid sequence (SEQ ID NO: 23).

Figure 2: Protein sequences of *A. calcoaceticus* PQQ-dependent s-GDH (top) and *A. baumannii* s-GDH (bottom) aligned according to sequence homology.

Figure 3: Illustration of pACSGDH vector referred to in Example 1 containing the wild-type or mutated DNA sequences of soluble PQQ-dependent glucose dehydrogenase.

Figure 4: Nucleotide (DNA) sequence of the pACSGDH vector referred to in Example 1 containing the wild-type DNA sequence of soluble PQQ-dependent glucose dehydrogenase (SEQ ID NO: 25).

Detailed description of the invention:

In a first embodiment the invention relates to a mutant of the soluble form of EC 1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH), said mutant characterized in that relative to the corresponding wild-type enzyme and with regard to at least one other selected sugar substrate, it has an at least two-fold improved substrate specificity for glucose .

WO 02/34919

PCT/EP01/12148

- 7 -

The directions given in this invention are easily applied for any known or even yet unknown isolate of s-GDH. These wild-type isolates can be used to assess the relative improvements in specificity for the variants generated therefrom.

The wild-type enzyme of *Acinetobacter calcoaceticus*-type strain LMD 79.41 which corresponds to SEQ ID NO: 24 is well-known and well-characterized. In case a different wild-type enzyme under investigation is not well-characterized it is advantageous to use the s-GDH from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as a reference. In a further preferred embodiment the properties of an improved variant of s-GDH are compared to this wild-type enzyme. The present invention therefore also relates to a mutant of s-GDH said mutant characterized in that relative to the wild-type enzyme of SEQ ID NO: 24 and with regard to at least one other selected sugar substrate, it has an at least two-fold increased substrate specificity for glucose.

As discussed above, two completely different enzyme families with glucose dehydrogenase activity, grouped together under EC1.1.99.17, are characterized to date. These two enzyme families, however, appear not be related to each other.

For the purpose of this invention only the soluble form of GDH (s-GDH) is relevant and improved variants thereof are discussed herein below.

It is known in the art that the wild-type DNA-sequence of a soluble PQQ-dependent glucose dehydrogenase can be isolated from strains of *Acinetobacter*. Most preferred is the isolation from *Acinetobacter calcoaceticus*-type strain LMD 79.41. The sequence of this wild-type s-GDH (the mature protein) is given in Figure: 1 and SEQ ID NO: 24. Other LMD strains of *Acinetobacter* may also be used as source of wild-type s-GDH. Such sequences can be aligned to the sequence obtained from *A. calcoaceticus* and sequence comparisons be made (see Figure: 2). It also appears feasible to screen DNA-libraries of other bacterial strains, as for example described for *E.coli* K-12 (Oubrie, A., et al., J Mol Biol 289 (1999) 319-33) above and to identify sequences related to s-GDH in such genomes. Such sequences and yet unidentified homologous sequences may be used to generate s-GDH mutants with improved substrate specificity for glucose.

The term "mutant" or "variant" in the sense of the present invention relates to a s-GDH protein which compared to a corresponding wild-type sequence exhibits at least one amino acid substitution. The expert in the field will appreciate that there are various possibilities

WO 02/34919

PCT/EP01/12148

- 8 -

to produce polynucleotides encoding for a polypeptide sequence of such mutated s-GDH. It is of course also possible to generate mutants comprising one or more additions or deletions of amino acids.

- 5 A mutant according to the present invention is characterized in that relative to the corresponding wild-type enzyme it has at least a two-fold improved substrate specificity for glucose as compared to at least one other selected sugar substrate.

- 10 In order to calculate the substrate specificity or cross-reactivity one easy way is to set the activity measured with glucose as substrate to 100% and to compare the activity measured with the other selected sugar to the glucose value. Sometimes, in order not to be redundant, simply the term specificity is used without making special reference to glucose on the one hand and a selected other sugar substrate on the other hand.

The expert in the field will appreciate that comparison of (re-)activities is best made at equimolar concentrations of the substrate molecules investigated using well-defined assay conditions. Otherwise corrections for differences in concentrations have to be made.

- 15 Standardized and well-defined assay conditions have to be chosen in order to assess (improvements in) specificity. The enzymatic activity of s-GDH for glucose as substrate as well as for other selected sugar substrates is measured as described in Example 6.

Based on these measurements cross-reactivity and (improvements in) specificity are assessed.

- 20 The s-GDH (cross-)reactivity for a selected sugar in percent is calculated as

Cross-reactivity [%] = (activity selected sugar/activity glucose) x 100%.

(Cross-)reactivity for maltose of wild-type s-GDH according to the above formula has been determined as about 105%. Wild-type s-GDH (cross-)reactivity for galactose has been measured as about 50% (cf. Table 1).

- 25 (Improved) specificity is calculated according to the following formula:

WO 02/34919

PCT/EP01/12148

- 9 -

$$\text{specificity (improvement)} = \frac{\text{activity glucose mutant} \quad \text{activity selected sugar wild-type}}{\text{activity glucose wild-type} \quad \text{activity selected sugar mutant}} \times \frac{\text{activity glucose wild-type}}{\text{activity selected sugar mutant}}$$

- As compared to the wild-type enzyme, a s-GDH form with an at least two-fold improvement in specificity for glucose versus maltose (maltose/glucose) accordingly with maltose as substrate has at most 52,5% of the activity as measured with glucose as substrate. Or, if, for example, a mutant s-GDH has a cross-reactivity for maltose of 20 % (determined and calculated as described above), this mutant as compared to the wild-type s-GDH therefore has a 5.25 fold improved substrate specificity (maltose/glucose).
- 10 The term "specific activity" for a substrate is well known in the art, it is preferably used to describe the enzymatic activity per amount of protein. Various methods are known to the art to determine specific activity of GDH molecules, using glucose or other sugars as substrates (Igarashi, S., et al., Biochem Biophys Res Commun 264 (1999) 820). One of the methods available for such measurement is described in detail in the examples section.
- 15 Whereas it is possible, to select many different sugar molecules and to investigate the glucose specificity of s-GDH in comparison to any such selected sugar molecule, it is preferred to select a clinically relevant sugar molecule for such a comparison. Preferred selected sugars are selected from the group consisting of mannose, allose, galactose, xylose, and maltose. More preferably, maltose or galactose are selected and mutant s-GDH is
- 20 tested for improved substrate specificity for glucose as compared to galactose or maltose. In a further preferred embodiment the selected sugar is maltose.

- It has surprisingly been found that the improvements in glucose specificity of mutated s-GDH, e.g., for maltose vs. glucose, are quite considerable. It is therefore further preferred that said substrate specificity for glucose as compared to the substrate specificity for at least
- 25 one of the selected other sugar substrates is improved at least three-fold. Other preferred embodiments comprise s-GDH mutants characterized by an improved substrate specificity for glucose, which is at least 5 times higher or also preferred at least 10 times higher, as compared to the other sugar molecule selected.

WO 02/34919

PCT/EP01/12148

- 10 -

Mutations in s-GDH lead in many cases to enzyme variants with drastically reduced specific activity for the substrate glucose. Such decrease in (absolute or overall) specific activity for the substrate glucose, however, may be critical for routine applications. Surprisingly it has been found that improved specificity for glucose must not go to the expense of a dramatically reduced overall specific activity. It is therefore preferred that the s-GDH with improved specificity towards the substrate glucose exhibits at least 10% of the specific activity for glucose as measured with the wild-type enzyme. It is of course more preferred that such mutated enzymes exhibit at least 20% or more preferred at least 50% of the respective glucose activity of wild-type s-GDH.

10 In a further preferred embodiment, the invention relates to a mutant of the soluble form of EC1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH), said mutant characterized in that

a) the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme and

15 b) the substrate specific reactivity towards maltose is 30% or less as compared to the wild-type enzyme.

The substrate specific reactivity (also termed specific activity) towards glucose is considered to be essentially equal to that of the wild-type enzyme if at least 50% of the original enzymatic activity for glucose of the wild-type enzyme is maintained. Also preferred are mutants exhibiting at least 80 % or more preferred, at least 90 % of the specific activity for glucose as measured for the wild-type enzyme.

Quite surprisingly it has been found, that it is possible to obtain such s-GDH mutants or variants, which compared to the wild-type s-GDH exhibit essentially equal enzymatic activity for glucose but, nonetheless, significantly reduced substrate specific reactivity towards other selected sugars, especially towards maltose. Mutants characterized in that the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme and in that the substrate specific reactivity towards maltose is 20% or less as compared to the wild-type enzyme are preferred. Further preferred are such mutants for which the maltose specific activity is 15 % or even only 10% or less of the maltose specific activity as measured for the corresponding wild-type enzyme, whereas the specific

WO 02/34919

PCT/EP01/12148

- 11 -

reactivity for glucose is essentially equal to the specific activity for glucose of the corresponding wild-type enzyme.

- In case the wild-type enzyme is not well-characterized it is preferred to use the s-GDH from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as reference. In a further preferred embodiment the properties of an improved variant of s-GDH are compared to this wild-type enzyme and the present invention therefore relates to a mutant of s-GDH said mutant characterized in that relative to the wild-type enzyme of SEQ ID NO: 24 it exhibits essentially equal enzymatic activity for glucose but, significantly reduced (at least 70% less) substrate specific reactivity towards at least one other selected sugar substrate.
- 10 Unexpectedly it has been found that it is possible to generate s-GDH mutants with improved substitute specificity and even more unexpectedly it has been found that it is only a few well-defined amino acid positions which are of major relevance in that respect.
- The achievements of the present invention are described in great detail by making reference to amino acid positions known from SEQ ID NO: 24, the wild-type sequence of s-GDH as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41. Amino acid positions in different s-GDH isolates corresponding to positions of SEQ ID NO: 24 are easily identified by appropriate sequence comparison. Preferably the PileUp program is used to assess homology or identity between such sequences. The amino acid positions given herein below shall be understood as amino acid positions of SEQ ID NO: 24 or of positions corresponding thereto in other s-GDH molecules, unless specific reference is made to a different SEQ ID NO or to a different s-GDH isolate. In order to avoid redundances only in a few cases a specific hint to the fact that corresponding positions in different isolates can be modified in the same way is given, whereas for convenience in most cases simply and only the corresponding position from SEQ ID NO: 24 is used.
- 25 Mutants comprising an amino acid substitution at the position corresponding to position 348 of s-GDH have been found to exhibit a striking effect on specificity for glucose. As demonstrated in table 1, a variety of s-GDH variants with improved specificity for glucose can be identified and generated, as long as at least the amino acid in position threonine 348 – as corresponding to wild-type s-GDH sequence position from *A. calcoaceticus* – is substituted with an appropriate other amino acid.
- 30

WO 02/34919

PCT/EP01/12148

- 12 -

A preferred embodiment of the present invention therefore relates to a mutant protein of PQQ-dependent s-GDH comprising an amino acid residue substitution at the amino acid position corresponding to position 348 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24).

- 5 It has also been found, that combined substitutions of amino acids at amino acid positions corresponding to positions 348 and 428 of SEQ ID NO: 24 are advantageous to generate s-GDH mutants or variants with significantly improved specificity for glucose.

- Residues 348 or 428 of s-GDH as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41 are not known from the art to contribute to the substrate binding of s-GDH (Oubrie, 10 A., et al., Embo J 18 (1999) 5187-94, ; Oubrie, A. and Dijkstra, B. W., Protein Sci 9 (2000) 1265-73). No chemical or physical explanation is at hand, why substitutions of these amino acid residues alters the substrate specificity of s-GDH for glucose as compared to other sugar molecules of interest.

- It has been found in addition that substitution of amino acid 76 also has a positive effect on 15 glucose specificity of s-GDH.

In a further preferred embodiment the mutated s-GDH is characterized in that the amino acid residue threonine at position 348 is substituted with an amino acid residue selected from the group consisting of alanine, glycine, and serine. In a most preferred embodiment glycine is used to substitute for threonine at position 348.

- 20 One group of preferred s-GDH variants according to this invention comprises a substitution of the amino acid residue at position 348 and at at least one of the following positions 76, 143, 168, 169 and 428.

- In yet a further embodiment a mutant protein of PQQ-dependent s-GDH comprises an amino acid residue substitution at position 428 of the correspondent wild-type sequence 25 from *Acinetobacter calcoaceticus*, in which the asparagine residue of the wild-type sequence is replaced by other appropriate amino acid residues. Preferably, such amino acid residue is selected from the group consisting of leucine, proline and valine. It is preferred to substitute the asparagine at position 428 with proline.

WO 02/34919

PCT/EP01/12148

- 13 -

It further has proved that the amino acid glutamine at position 76 can be substituted to improve on the problems imposed by s-GDH cross-reactivity with other sugar molecules. Sequence positions of other s-GDH isolates corresponding to this sequence position are easily identified by a homology search based on SEQ ID NO:3. In another preferred
5 embodiment the mutant according to the present invention therefore comprises a substitution of glutamine at position 76 of the corresponding wild-type sequence from *Acinetobacter calcoaceticus*.

It is preferred to select the amino acid used in such substitution at a position corresponding to position 76 in SEQ ID NO: 24 from the group consisting of alanine, aspartic acid,
10 glutamic acid, glycine, methionine, proline and serine.

As described above, a substitution of the amino acid in position 348 of the s-GDH sequence corresponding to the wild-type sequence isolated from *A. calcoaceticus*, can be used to significantly improve the glucose specificity of s-GDH. Further improved mutants are obtained by providing a mutant s-GDH protein comprising at least two amino acid
15 substitutions, wherein the amino acid corresponding to amino acid position 348 of SEQ ID NO : 24 is substituted.

A further embodiment of the present invention therefore is a mutant s-GDH comprising at least two amino acid residue substitutions at an amino acid position corresponding to a position of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24),
20 said substituted amino acid positions being selected from the group consisting of positions 16, 22, 76, 116, 120, 127, 143, 168, 169, 171, 177, 227, 230, 231, 245, 255, 277, 295, 299, 308, 317, 341, 348, 349, 355, 422, 428 and 438, wherein the amino acid residue T348 is replaced. It is further preferred, that a s-GDH variant with the at least two substituted amino acid residues comprises a substitution in position 348 and at least one additional substitution
25 selected from the group of positions comprising positions 76, 143, 168, 169, and 428.

In a further preferred embodiment the at least two amino acid positions which are substituted in a mutant s-GDH are selected from the group consisting of amino acid positions 76, 348, and/or 428.

Mutants comprising substitutions at amino acid residues corresponding to positions 348
30 and 428 have been found as very advantageous for improving the specificity of s-GDH for

WO 02/34919

PCT/EP01/12148

- 14 -

glucose in comparison to other sugar substrates. It is especially preferred to design and select mutants of s-GDH, which comprise a substitution at both the positions 348 and 428. Most preferred are mutants comprising the preferred substitutions as described above at both these positions. A s-GDH variant comprising T348G and N428P is most preferred.

- 5 The terminology T348G and N428P is known to the art to indicate that threonine at position 348 is replaced by glycine and glutamine and position 428 is replaced by proline.

Mutant s-GDH proteins comprising in addition to substitutions at positions 348 and 428 also substitutions at positions 76, 127 and 143, also represent preferred embodiments of the present invention.

- 10 Further preferred examples of mutated s-GDH proteins according to the present invention comprise amino acid substitutions at positions 76 and 348 and also such mutants comprising substitutions at positions 76 and 428. In yet another preferred embodiment the mutated s-GDH protein according to the present invention comprises substitutions of the amino acid residues at positions 76, 348 and 428.
- 15 In yet a further preferred embodiment the s-GDH variant according to the present invention comprises at least three amino acid substitutions, the at least three substituted amino acid residues corresponding to amino acid positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 171, 227, 230, 245, 341, 348,
- 20 349, and 428, wherein both the amino acid residues T348 and N428 are substituted. Preferably such triple mutants comprise at least one of the following substitutions: Y171G, H227F, P230H, E245D or M341V.

- Preferred s-GDH variants with highly improved specificity for glucose comprise substitutions at positions 348 and 428 in combination with substitutions at positions 245
- 25 or 341, or both.

Amino acid sequence analysis revealed that the sequence motives found in wild-type s-GDH from *A. calcoaceticus* on the one hand and *A. baumannii* on the other hand appear to be very conservative around the positions of major relevance to improve the specificity for

WO 02/34919

PCT/EP01/12148

- 15 -

glucose as identified in the present invention, i.e. positions 76, 348, and 428, as corresponding to wild-type s-GDH from *A. calcoaceticus* (c.f., Figure 2).

A preferred embodiment according to the present invention therefore is a mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of WPXaaVAPS (SEQ ID NO: 1), wherein said Xaa residue is an amino acid residue other than threonine. SEQ ID NO:1 corresponds to position 346-352 of *A. calcoaceticus* wild-type s-GDH or position 347-353 of *A. baumannii* wild-type s-GDH.

Further preferred is an s-GDH mutant wherein said Xaa in SEQ ID NO: 1 represents alanine, glycine or serine, most preferred, Xaa represents glycine.

- 10 A mutant of PQQ-dependent s-GDH, comprising the amino acid sequence of TAGXaaVQK (SEQ ID NO: 2), wherein said Xaa residue is an amino acid residue other than asparagine, is another preferred embodiment of the invention. SEQ ID NO:2 corresponds to position 425-431 of *A. calcoaceticus* wild-type s-GDH or to position 426-432 of *A. baumannii* wild-type s-GDH.
- 15 Preferably the s-GDH mutant comprising SEQ ID NO:2 is characterized in that said Xaa residue is selected from the group consisting of leucine, proline and valine, most preferred Xaa is a proline residue.

- Numerous possibilities are known in the art to produce mutant proteins. Based on the important findings of the present invention disclosing the critical importance of amino acid positions 348 and 428 and also the utility of position 76, the skilled artisan now can easily produce further appropriate variants of s-GDH. Such variants for example can be obtained by the methods known as random mutagenesis (Leung, D. W., et al., Technique 1 (1989) 11-15) and/or directed mutagenesis (Hill, D. E., et al., Methods Enzymol 155 (1987) 558-68). An alternative method to produce a protein with the desired properties is to provide chimaeric constructs, which contain sequence elements from at least two different sources or to completely synthesize an appropriate s-GDH gene. Such procedures known in the art may be used in combination with the information disclosed in the present invention to provide mutants or variants of s-GDH comprising at least one amino acid substitution at a sequence position corresponding to positions 348, and/or 428 of SEQ ID NO: 24.

WO 02/34919

PCT/EP01/12148

- 16 -

A s-GDH variant according to the present invention can e.g., be produced by starting from a s-GDH gene as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as well as by starting from a homologous sequence. In the context of this application the term "homologous" is meant to comprise wild-type s-GDH as isolated from other microorganisms, provided that the sequence homology as compared to SEQ ID NO: 24 is at least 90 %. With other words, after appropriate alignment using the PileUp program, at least 90 % of the amino acids of that s-GDH are identical to the amino acids described in SEQ ID NO: 24.

It will be understood that variations of DNA and amino acid sequences naturally exist, or may be intentionally introduced using methods known in the art. These variations may result in up to 10 % amino acid differences in the overall sequence, due to deletions, substitutions, insertions, inversions or additions of one or more amino acid residues in said sequence as compared to SEQ ID NO: 24. Such amino acid substitutions may be made, for example, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, tyrosine. Other contemplated variations include salts and esters of the afore mentioned polypeptides, as well as precursors of the aforementioned polypeptides, for example, precursors having N-terminal substitution such as methionine, N-formylmethionine used as leader sequences. Such variations may be made without necessarily departing from the scope and the spirit of the present invention.

According to procedures known in the state of the art or according to the procedures given in the examples section, it is possible to obtain polynucleotide sequences coding for any of the s-GDH mutants as discussed above. The invention therefore comprises also isolated polynucleotide sequences encoding s-GDH mutant proteins as described above.

The present invention further includes an expression vector comprising a nucleic acid sequence according to the present invention operably linked a promoter sequence capable of directing its expression in a host cell.

WO 02/34919

PCT/EP01/12148

- 17 -

The present invention further includes an expression vector comprising a nucleic acid sequence according to the present invention operably linked to a promoter sequence capable of directing its expression in a host cell. Preferred vectors are plasmids such as pACSGDH shown in Figures 3 and 4.

- 5 Expression vectors useful in the present invention typically contain an origin of replication, a promoter located upstream in the DNA sequence and are followed by the DNA sequence coding for all or part of s-GDH variants. The DNA sequence coding for all or part of the s-GDH variants is followed by transcription termination sequences and the remaining vector. The expression vectors may also include other DNA sequences known in the art, for
- 10 example, stability leader sequences which provide for stability of the expression product, secretory leader sequences which provide for secretion of the expression product, sequences which allow expression of the structural gene to be modulated (e.g., by the presence or absence of nutrients or other inducers in the growth medium), marking sequences which are capable of providing phenotypic selection in transformed host cells, and the sequences
- 15 which provide sites for cleavage by restriction endonucleases.

- The characteristics of the actual expression vector used must be compatible with the host cell, which is to be employed. For example, when cloning in an *E.coli* cell system, the expression vector should contain promoters isolated from the genome of *E.coli* cells (e.g., , *lac*, or *trp*). Suitable origins of replication in *E.coli* various hosts include, for example, a
- 20 ColE1 plasmid replication origin. Suitable promoters include, for example, *lac* and *trp*. It is also preferred that the expression vector includes a sequence coding for a selectable marker. The selectable marker is preferably an antibiotic resistance gene. As selectable markers, ampicillin resistance, or canamycin resistance may be conveniently employed. All of these materials are known in the art and are commercially available.
- 25 Suitable expression vectors containing the desired coding and control sequences may be constructed using standard recombinant DNA techniques known in the art, many of which are described in Sambrook et al. (1989).

- The present invention additionally concerns host cells containing an expression vector which comprises a DNA sequence coding for all or part of the mutant s-GDH. The host
- 30 cells preferably contain an expression vector that comprises all or part of one of the DNA sequences having one or more mutations shown in Table 1. Further preferred are the host

WO 02/34919

PCT/EP01/12148

- 18 -

cells containing an expression vector comprising one or more regulatory DNA sequences capable of directing the replication and/or the expression of, and operatively linked to a DNA sequence coding for, all or part of mutant s-GDH. Suitable host cells include, for example, *E.coli* HB101 (ATCC 33694) available from Pomega (2800 Woods Hollow Road, Madison, WI, USA), XL1-Blue MRF available from Stratagene (11011 North Torrey Pine Road, La Jolla, CA, USA) and the like.

Expression vectors may be introduced into host cells by various methods known in the art. For example, transformation of host cells with expression vectors can be carried out by polyethylene glycol mediated protoplast transformation method (Sambrook et al. 1989). However, other methods for introducing expression vectors into host cells, for example, electroporation, biolistic injection, or protoplast fusion, can also be employed.

Once an expression vector containing an s-GDH variant has been introduced into an appropriate host cell, the host cell may be cultured under conditions permitting expression of the desired s-GDH variants. Host cells containing an expression vector which contains a DNA sequence coding for all or part of the mutant s-GDH are, e.g., identified by one or more of the following general approaches: DNA hybridization, the presence or absence of marker gene functions, assessment of the level of transcription as measured by the production of s-GDH mRNA transcripts in the host cell, and detection of the gene product immunologically. Preferably transformed host cells are identified by enzyme assay, e.g., colourimetric detection.

The present invention also teaches the generation and screening of s-GDH variants. Random mutagenesis and saturation mutagenesis is performed as known in the art. Variants are analyzed for substrate specificity for glucose, maltose as well as other sugars. The assay conditions chosen are adapted to ensure that the expected small enhancements brought about e.g., by a single amino acid substitution, can be measured. This has been accomplished by adjusting the assay conditions such that the wild type (or parent) enzyme activity is close to the lower detection limit. One mode of selection or screening of appropriate mutants is given in Example 3. Any change or improvement as compared over the wild-type enzyme this way can be clearly detected.

It should, of course, be understood that not all expression vectors and DNA regulatory sequences would function equally well to express the DNA sequences of the present

WO 02/34919

PCT/EP01/12148

- 19 -

invention. Neither will all host cells function equally well with the same expression system. However, one of ordinary skill in the art may make a selection among expression vectors, DNA regulatory sequences, and host cells using the guidance provided herein without undue experimentation and without departing from the scope of the present invention.

- 5 The invention also relates to a process for producing s-GDH variants of the current invention comprising culturing a host cell of the invention under conditions suitable for production of the mutant s-GDH of the invention. For bacterial host cells, typical culture conditions are liquid medium containing the appropriate antibiotic and induction agent. Typical appropriate antibiotics include ampicillin, canamycin, chloroamphenicol,
10 tetracyclin and the like. Typical induction agents include IPTG, glucose, lactose and the like.

- It is preferred that the polypeptides of the present invention are obtained by production in host cells expressing a DNA sequence coding the mutant s-GDH. The polypeptides of the present invention may also be obtained by *in vitro* translation of the mRNA encoded by a
15 DNA sequence coding for the mutant s-GDH. For example, the DNA sequences may be synthesized as described above and inserted into a suitable expression vector, which in turn may be used in an *in vitro* transcription/translation system.

- An expression vector comprising an isolated polynucleotide as defined and described above operably linked to a promoter sequence capable of promoting its expression in a cell-free
20 peptide synthesis system represents another preferred embodiment of the present invention.

- The polypeptides produced e.g. by procedures as describe above, may then be isolated and purified using various routine protein purification techniques. For example, chromatographic procedures such as ion exchange chromatography, gel filtration
25 chromatography and affinity chromatography may be employed.

- One of the major applications of the improved s-GDH variants of this invention is for the use in test strips to monitor blood-glucose level in diabetic patients. Due to the insensitivity of PQQ-dependent glucose dehydrogenase towards oxygen, a system using the improved s-GDH variants is less prone to interference by oxygen than systems based on glucose
30 oxidase. More important, since the s-GDH variants have improved specificity towards

WO 02/34919

PCT/EP01/12148

- 20 -

glucose and significantly decreased relative enzymatic activity towards other sugars, the interference due maltose, galactose, and/or other related sugars which may be present in a sample to be analyzed is significantly reduced. Of course many kinds of samples may be investigated. Bodily fluids like serum, plasma, intestinal fluid or urine are preferred sources
5 for such samples.

The invention also comprises a method of detecting, determining or measuring glucose in a sample using a s-GDH mutant according to the present invention. It is especially preferred that the improved method for detection of glucose in a sample is characterized in that said detection, determination or measurement of glucose is performed using a sensor or test
10 strip device.

Also within the scope of the present invention is a device for the detection or measurement of glucose in a sample comprising a s-GDH mutant according to this invention as well as other reagents required for said measurement.

The s-GDH variants with improved substrate specificity of this invention can also be used
15 to great advantage in biosensors (D'Costa, E. J., et al., Biosensors 2 (1986) 71-87; Laurinavicius, V., et al., Analytical Letters 32 (1999) 299-316; Laurinavicius, V., et al., Monatshefte fuer Chemie 130 (1999) 1269-1281) for online monitoring of glucose in a sample or a reactor. For this purpose, the s-GDH variants can, for example, be used to coat an oxygen-insensitive glassy electrode with an osmium complex containing a redox
20 conductive epoxy network (Ye et al., 1993, supra) for more accurate determination of the glucose concentration.

There are also other possible applications of the s-GDH variants with the improved substrate specificity according to this invention. For example, these s-GDH variants may be used in an aldonic acid production process. Wild-type s-GDH has a high turnover in
25 substrate oxidation producing gluconic and other aldonic acids. By using the s-GDH variants, which are more specific for glucose, the production of gluconic acid would result in much less byproducts. With other s-GDH variants of different substrate specificity, it is possible to produce different aldonic acids as required.

In the following examples, all reagents, restriction enzymes, and other materials were
30 obtained from Roche Diagnostics Germany, unless other commercial sources are specified,

WO 02/34919

PCT/EP01/12148

- 21 -

and used according to the instructions given by the suppliers. Operations and methods employed for the purification, characterization and cloning of DNA are well known in the art (Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Wiley Verlag) and can be adapted as required by the skilled artisan.

- 5 The following examples further illustrate the present invention. These examples are not intended to limit the scope of the present invention, but provide further understanding of the invention.

Example 1

- 10 Cloning and expression of the wild-type *A. calcoaceticus* soluble PQQ dependent glucose dehydrogenase in *E. coli*

The s-GDH gene was isolated from *Acinetobacter calcoaceticus* strain LMD 79.41 according to standard procedures. The wild-type s-GDH gene was subcloned into a plasmid containing the mgl promoter for adjustabel expression (cf. Patent application WO
15 88/09373). The new construct was called pACSGDH (see Figures 3 and 4). The recombinant plasmids was introduced into a host organism selected from the *E.coli* group. These organisms were then cultivated under appropriate conditions and colonies showing s-GDH activity selected.

The plasmid pACSGDH was isolated from a 200 ml over-night culture of the clone
20 mentioned above using the QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturers protocol. The plasmid was resuspended in 1 ml bidest. water. The concentration of the plasmid was determined using a Beckman DU 7400 Photometer. The yield was 600 µg. Then the quality of the plasmid was determined by agarose gel electrophoresis.

- 25 Example 2:

Mutagenic PCR

To generate random mutations in the s-GDH-gene, mutagenic PCR (polymerase chain reaction) was performed. The pACSGDH plasmid and the DNA sequence encoding the
30 mutated enzymes (PCR product from mutagenic PCR) were digested with the restriction

WO 02/34919

PCT/EP01/12148

- 22 -

enzymes *Sph* I and *Eco* RI. The products were gel purified. The digested DNA sequences were ligated and an aliquot of the ligation reaction mixture was used to transform competent *E.coli* cells. The transformants were subsequently selected on LB plates containing ampicillin.

- 5 To assay, individual colonies were chosen, grown over night in LB medium containing ampicillin and subjected to screening (see Example 3) .

Mutagenic PCR reaction mixture:

40 ng pACSGDH

1 x buffer without MgCl₂ (Roche Diagnostics GmbH, Cat. 1699 105)

- 10 dCTP, dTTP 1mM

dATP, dGTP 0.2 mM (Roche Diagnostics GmbH, Cat. 1969 064)

40 pmol GF23-Primer (5'-CGC GCA CGC GCA TGC CGC CGA TGT TC) (= SEQ ID NO: 4)

40 pmol GR23 (5'-GAC GGC CAG TGA ATT CTT TTC TA) (= SEQ ID NO: 5)

- 15 7 mM MgCl₂

0.6 mM MnCl₂

5 U Taq DNA polymerase (Roche Diagnostics GmbH, Cat. 1146 165)

Gene Amp PCR System 2400 (Perkin Elmer), 30 cycles: 95 °C 1 min, 45 °C 2 min, 72 °C 2 min

- 20 - Purification of the PCR products using the High Pure PCR Product Purification Kit from Roche Diagnostics GmbH (Cat. 1 732 676) according to the manufacturers protocol.
- Digestion of the PCR-fragments with 25 U *Sph*I (Roche Diagnostics GmbH, Cat. 606 120) in 1 x buffer H (Roche Diagnostics GmbH, Cat. 1 417 991) at 37 °C over night;

WO 02/34919

PCT/EP01/12148

- 23 -

addition of 25 U *EcoRI* (Roche Diagnostics GmbH, Cat. 703 737) and further digestion for 3.5 hours

- Digestion of 50 µg pACSGDH with 180 U *SphI* and 180 U *EcoRI* in 1 x buffer H for 4 hours at 37 °C.
- 5 - Gel electrophoresis of the digested pACSGDH and the digested fragments using agarose gels (0.8 %)
- Extraction of the DNA molecules using QIAquick Gel Extraction Kit (Qiagen, Cat. 28706) according to the manufacturers protocol
- Determination of the concentration of the fragments and the digested vector using a
10 Beckman DU 7400 Photometer
- Determination of the quality of the purified products by agarose gel electrophoresis
- Ligation of 100 ng digested vector with 140 ng mPCR-fragments using 1 U T4-DNA-Ligase (Roche Diagnostics GmbH, Cat. 481 220) in a volume of 20 µl at 16 °C over night
- 15 - Electroporation of electrocompetent XL1F- cells (Stratagene) with 1 µl of the ligation reaction with 2.5 KV in 0.2 cm cuvettes using a BioRad *E. coli* Pulser (BioRad)
- After growth in 1 ml LB at 37 °C for one hour, bacteria were plated on LB-Ampicillin Agar plates (100 µg / ml Ampicillin) and grown over night at 37 °C.
- 50 % of these clones expressing mutated s-GDH were active using the following
20 screening method.

WO 02/34919

PCT/EP01/12148

- 24 -

Example 3:

Screening

The mutant colonies on agar plates described above were picked in microtiter plates (mtp) containing 200 µl LB-Ampicillin-media/well and incubated over night at 37 °C. These plates are called master plates.

From each master plate, 5 µl sample/well was transferred to a mtp containing 5 µl per/well of B (B=Bacterial Protein Extraction Reagent; Pierce No. 78248) for cell disruption and 240 µl of 0.0556 mM pyrrolo-quinoline quinone(PQQ); 50 mM Hepes; 15 mM CaCl₂ pH 7.0/well for activation of s-GDH were added. To complete the formation of the holoenzyme, the mtp was incubated at 25°C for 2 hours and at 10 °C over night. This plate is called working plate.

From the working plate 2 x 10 µl sample/hole were transferred to two empty mtps. After that, one was tested with glucose and the other with maltose or other selected sugar molecules as a substrate. All sugar molecules were used in equimolar concentrations.

The dE/min was calculated and the value using glucose as substrate was set to 100% activity. The value obtained with the other sugar was compared to the glucose value and calculated in percent activity ((dE/min Maltose/dE Glucose)*100). This is equivalent to the cross-reactivity of the (mutant) enzyme.

20 Example 4:

Sequencing of mutant s-GDH gene from mutagenic PCR

The plasmid containing the mutant s-GDH gene that leads to 50 % maltose/glucose activity was isolated (High Pure Plasmid Isolation Kit, Roche Diagnostics GmbH, No. 1754785) and sequenced using an ABI Prism Dye Terminator Sequencing Kit and ABI 3/73 and 3/77 sequencer (Amersham Pharmacia Biotech).

Following primers were used:

WO 02/34919

PCT/EP01/12148

- 25 -

Sense strand: GDH F2 : 5'-TTA ACG TGC TGA ACA GCC GG-3' (= SEQ ID NO: 6)

GDH F3: 5'-GAT GCT GAT GGG CAG AAT GG-3' (= SEQ ID NO: 7)

GDH F4: 5'-ATA TGG GTA AAG TAC TAC GC -3' (= SEQ ID NO: 8)

GDH F5: 5'-ACG ATC CAA CTT GTG GAG AG-3' (= SEQ ID NO: 9)

5 Antisense strand: GDH R1: 5'-CGA TTA AGT TGG GTA ACG CC-3' (= SEQ ID NO: 10)

GDH R2: 5'-ATA CGG AAA ATG ACA CCA CG-3' (= SEQ ID NO: 11)

GDH R3: 5'-GGG CCT TGT TCA GAC TGC AA-3' (= SEQ ID NO: 12)

GDH R4: 5'-CAA GAC GAC CTG ACT GAT GG-3' (= SEQ ID NO: 13)

GDH R5: 5'-CAT AAC AAC GCG TGC GGCTT-3' (= SEQ ID NO: 14)

10 Results:

=>6 mutations on DNA sequence level

⇒ 4 mutations on amino acid level:

at position 340 (mature enzyme) change from E to G

15 at position 348 (mature enzyme) change from T to S

at position 369 (mature enzyme) change from N to H

at position 413 (mature enzyme) change from S to N

Example 5:

20 s-GDH mutants obtained by saturation mutagenesis

The QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cat. 200518) was used to substitute successively wild type amino acids at defined positions of the s-GDH-protein or

WO 02/34919

PCT/EP01/12148

- 26 -

of s-GDH-mutants (plasmide purification as discribed above) with other random amino acids.

The 5'- and the 3'-primer used for mutagenesis were complementary to each other and contained NNN in a central position. These nucleotides were flanked by 12 to 16 nucleotides at each end. The sequences of the nucleotides were identical to the cDNA-strand or to the complementary cDNA-strand flanking the codon for the amino acid that had to be substituted. Instead of the codon, the primer contained NNN therefore the oligonucleotides code for every codon.

For every defined position, one PCR reaction was performed.

10 The PCR-reactions and the *DpnI* digestions were performed according to the manual.

After that, 1 µl of each reaction was used for the electroporation of XL1F- cells. Cells were grown and the s-GDH activity of the clones was determined as described above.

To ensure statistically that all 20 amino acids variants were screened, 200 clones were tested for each position.

15 The following primers where used:

for position 340 Sense strand EGF 5'-TCC AAC TTG TGG ANN N AT GAC CTA
CAT TT-3' (= SEQ ID NO: 15)

Antisense strand EGR 5'- AAA TGT AGG TCA TNN NTC CAC AAG TTG GA-3' (= SEQ ID NO: 16)

20 for position 348 Sense strand TSF 5'- CAT TTG CTG GCC ANN NGT TGC ACC GTC AT-
3' (= SEQ ID NO: 17)

Antisense strand TSR 5'- ATG ACG GTG CAA CNN NTG GCC AGC AAA TG-3' (= SEQ ID NO: 18)

WO 02/34919

PCT/EP01/12148

- 27 -

for position 369 Sense strand NHF 5'-TAC TGG TTG GGA ANN NAC ATT ATT GGT TC
-3' (= SEQ ID NO: 19)

Antisense strand NHR 5'- GAA CCA ATA ATG TNN NTT CCC AAC CAG TA-3' (= SEQ ID NO: 20)

- 5 for position 413 Sense strand SNF 5'-TGA TGT GAT TGC ANN NCC AGA TGG GAA TG
-3' (= SEQ ID NO: 21)

Antisense strand SNR 5'- CAT TCC CAT CTG GNN NTG CAA TCA CAT CA-3' (= SEQ ID NO: 22)

Results:

- 10 The amino acid changes at positions 340, 369 and 413 didn't change the substrate specificity. Only the wobble at position 348 did yield clones with a substrate specificity from 25-100 % (maltose/glucose).

- Numerous rounds of mutagenic PCR and saturation mutagenesis were performed. It was
15 found and confirmed that positions 348 and 428 are of major importance and that exchange of other amino acids may further improve the specificity for glucose of mutated s-GDH. Representative data and positions are given in table 1.

Table 1: Examples for s-GDH-variants with improved specificity for glucose

- 20 Abbreviations: n.t. = not tested

SA = specific activity (U/mg protein) with glucose as substrate

Changed amino acid to wildtype sequence	Glucose conversion	Maltose conversion	Galactose conversion	SA
wild-type	100%	105%	50%	1000
340 E to G 348 T to S 369 N to H 413 S to N	100%	50%	25%	700
22 I to L	100%	123%	14%	178

WO 02/34919

PCT/EP01/12148

- 28 -

295 Q to L 422 L to I				
348 T to D	100%	80%	n.t.	n.t.
348 T to A	100%	67%	n.t.	n.t.
348 T to G	100%	22%	20%	910
428 N to P 348 T to G	100%	8%	25%	n.t.
428 N to V 348 T to G	100%	22%	22%	n.t.
127 T to M 143 D to Q 348 T to G 428 N to P	100%	1%	32%	n.t.
76 Q to A 348 T to G	100%	17%	n.t.	n.t.
76 Q to M 348 T to G	100%	18%	n.t.	n.t.
76 Q to D 348 T to G	100%	17%	n.t.	n.t.
76 Q to P 348 T to G	100%	17%	n.t.	n.t.
76 Q to S 348 T to G	100%	17%	n.t.	n.t.
76 Q to G 348 T to G	100%	20%	n.t.	n.t.
76 Q to E 348 T to G	100%	17%	n.t.	n.t.
143 D to E 348 T to G	100%	17%	n.t.	n.t.
171 Y to H 348 T to G 308 K to N	100%	19%	n.t.	n.t.
171 Y to D 348 T to G 317 F to V	100%	18%	n.t.	n.t.
127 T to S 169 L to H 348 T to G 355 Y to H	100%	11%	n.t.	n.t.
16 N to D 120 T to S	100%	22%	n.t.	n.t.

WO 02/34919

PCT/EP01/12148

- 29 -

177 Q to R 277 Y to H 348 T to G				
116 I to T 255 N to T 299 K to R 348 T to G	100%	20%	n.t.	n.t.
227 H to Y 348 T to G 438 N to S	100%	18%	n.t.	n.t.
341 M to V 348 T to G	100%	20%	n.t.	n.t.
348 T to G 349 V to G 428 N to P	100%	10%	n.t.	n.t.
171 Y to G 230 P to H 348 T to G 428 N to P	100%	3%	n.t.	n.t.
230 P to H 348 T to G 428 N to P	100%	10%	n.t.	200
227 H to F 230 P to H 348 T to G 428 N to P	100%	6%	n.t.	n.t.
143 D to E 348 T to G	100%	17%	n.t.	n.t.
143 D to E 348 T to G 428 N to P	100%	1%	32%	n.t.
169 G to X 230 P to H 348 T to G 428 N to P	100%	2%	n.t.	n.t.

WO 02/34919

PCT/EP01/12148

- 30 -

Example 6:**Purification of mutant s-GDH T348G**

The grown cells (LB-Amp. 37 °C) were harvested and resuspended in potassium phosphate
5 buffer pH 7.0. Cell disruption was performed by French Press passage (700-900 bar). After
centrifugation the supernatant was applied to a S-Sepharose (Amersham Pharmacia Biotec)
column equilibrated with 10 mM potassium phosphate buffer pH 7.0. After washing, the s-
GDH was eluted using a salt gradient 0-1 M NaCl. The fractions showing s-GDH activity
were pooled, dialysed against potassium phosphate buffer pH 7.0 and re-chromatographed
10 on re-equilibrated S-sepharose column. The active fractions were pooled and subjected to
a gel filtration using a Superdex® 200 column (Amersham Pharmacia Biotec). The active
fractions were pooled and stored at -20 °C.

Enzyme assay and Protein determination of mutant T348G and wildtype s-GDH

Protein determination was performed using the Protein Assay Reagent no. 23225 from
15 Pierce (calibration curve with BSA, 30 Min. 37 °C).

The GDH samples were diluted to 1 mg protein/ml with 0.0556 mM pyrrolo-quinoline
quinone(PQQ); 50 mM Hepes; 15 mM CaCl₂ pH 7.0 and incubated at 25°C for 30 minutes
for reconstitution or activation.

After activation 50 µl of sample were added to 1000 µl of a 0.2 M citrate buffer solution (pH
20 5.8; at 25°C) containing 0.315 mg (4-(dimethylphosphinylmethyl)-2-methyl-pyrazolo-
[1.5a]-imidazol-3-yl)-(4-nitrosophenyl)-amine (see patent US 5,484,708)/ml as a mediator
and 33 mM sugar).

Extinction at 620 nm is monitored during the first 5 minutes at 25 °C.

One Unit enzyme activity corresponds the conversion of 1 mMol mediator/min under the
25 above assay conditions

Calculation: Activity = (total volume * dE/min [U/ml]) : (ε * sample volume * 1)

(ε = coefficient of extinction; in this example $\epsilon_{620\text{ nm}} = 30[1^* \text{ mmol}^{-1} * \text{ cm}^{-1}]$).

WO 02/34919

PCT/EP01/12148

- 31 -

The assay was performed with glucose, maltose and galactose (Merck, Germany).

Results:

Sample	Specific activity U/mgProtein (glucose as substrate)	% maltose/glucose conversion	% galactose/glucose conversion
wilde-type	1000	105%	50%
Mutant T348G	910	22%	20%

5 Example 7: Determination of glucose in the presence or absence of maltose

The wild-type and mutant T348G of s-GDH were applied for glucose determination. The reference samples contained 65 mg glucose/dl. The "test"-sample contained 65 mg glucose/dl and 130 mg/dl maltose. The same amounts of GDH activity (U/ml; see enzyme
10 assay) were used for each assay.

In a cuvette was mixed:

1 ml 0.315 mg (4-(dimethylphosphinylmethyl)-2-methyl-pyrazolo-[1.5a]-imidazol-3-yl)-(4-nitrosophenyl)-amine ml/0.2 M citrate pH 5.8

0.015 ml sample (glucose or glucose + maltose)

15 The assay was started adding 0.050 ml 90 U/ml s-GDH . The change of absorption at 620 nm was monitored. After 5 minutes constant values were observed and the dE/5 min calculated. The value obtained measuring the reference sample with wild-type s-GDH was set to 100%. The other values were compared to this reference value and calculated in %.

Results:

20

	65 mg/dl glucose	65 mg/dl glucose and 130 mg/dl maltose
wild-type s-GDH	100%	190%
mutant s-GDH T348G	100%	130%

It can be clearly seen that the „glucose-value“ measured is markedly less impaired when the mutated s-GDH is used in this determination.

WO 02/34919

PCT/EP01/12148

- 32 -

List of References

- Anthony C., 1996. Quinoprotein-catalysed reactions. *Biochem. J.* 320(3):697-711
- Anthony C., Ghosh M., 1997. The structure and function of PQQ-containing quinoproteins. *Curr. Sci.* 72(10):716-727
- 5 Anthony, C., *Biochem J* 320 (1996) 697-711
- Anthony, C. and Ghosh, M., *Current Science* 72 (1997) 716-727
- Anthony, C. and Ghosh, M., *Prog Biophys Mol Biol* 69 (1998) 1-21
- Anthony, C., *Biochem Soc Trans* 26 (1998) 413-7
- Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Wiley Verlag
- 10 Cleton-Jansen, A. M., et al., *Antonie Van Leeuwenhoek* 56 (1989) 73-9
- Cleton-Jansen, A. M., et al., *J Bacteriol* 170 (1988) 2121-5
- Cleton-Jansen, A. M., et al., *Mol Gen Genet* 217 (1989) 430-6
- Davidson, V. L. in "Principles and applications of quinoproteins" (1993) the whole book, New York, Marcel Dekker
- 15 D'Costa, E. J., et al., *Biosensors* 2 (1986) 71-87
- Dokter, P., et al., *FEMS Microbiology Letters* 43 (1987) 195-200
- Dokter, P., et al., *Biochem J* 239 (1986) 163-7
- Dokter, P., et al., *Biochem J* 254 (1988) 131-8
- Duine, J. A. Energy generation and the glucose dehydrogenase pathway in *Acinetobacter* in
- 20 "The Biology of *Acinetobacter*" (1991) 295-312, New York, Plenum Press
- Duine, J. A., *Biosens. Bioelectronics* 10 (1995) 17-23
- Duine, J. A., et al., *Arch Microbiol* 131 (1982) 27-31
- Duine, J. A., *Eur J Biochem* 200 (1991) 271-84
- Goodwin, P. M. and Anthony, C., *Adv Microb Physiol* 40 (1998) 1-80
- 25 Hill, D. E., et al., *Methods Enzymol* 155 (1987) 558-68
- Igarashi, S., et al., *Biochem Biophys Res Commun* 264 (1999) 820-4
- Kaufmann, N., et al. Development and evaluation of a new system for determining glucose from fresh capillary blood and heparinised venous blood in "Glucotrend" (1997) 1-16, Mannheim, Boehringer Mannheim GmbH
- 30 Laurinavicius, V., et al., *Analytical Letters* 32 (1999) 299-316
- Laurinavicius, V., et al., *Monatshefte fuer Chemie* 130 (1999) 1269-1281
- Leung, D. W., et al., *Technique* 1 (1989) 11-15
- Matsushita, K. and Adachi, O. Bacterial quinoproteins glucose dehydrogenase and alcohol dehydrogenase in "Principles and applications of Quinoproteins" (1993) 47-63,
- 35 New York, Marcel Dekker

WO 02/34919

PCT/EP01/12148

- 33 -

- Matsushita, K., et al., *Antonie Van Leeuwenhoek* 56 (1989) 63-72
Matsushita, K., et al., *Biochemistry* 28 (1989) 6276-80
Matsushita, K., et al., *Bioscience Biotechnology & Biochemistry* 59 (1995) 1548-1555
Oliphant, A. R., et al., *Gene* 44 (1986) 177-83
- 5 Olsthoorn, A. J. and Duine, J. A., *Arch Biochem Biophys* 336 (1996) 42-8
Olsthoorn, A. J. and Duine, J. A., *Biochemistry* 37 (1998) 13854-61
Oubrie, A. and Dijkstra, B. W., *Protein Sci* 9 (2000) 1265-73
Oubrie, A., et al., *Embo J* 18 (1999) 5187-94
Oubrie, A., et al., *J Mol Biol* 289 (1999) 319-33
- 10 Oubrie, A., et al., *Proc Natl Acad Sci U S A* 96 (1999) 11787-91
Sambrook, J., et al. - in "Molecular Cloning: A Laboratory Manual" (1989) -, Cold Spring Harbour, NY, Cold Spring Harbour Laboratory Press
Wens, R., et al., *Perit Dial Int* 18 (1998) 603-9
Ye, L., et al., *Anal. Chem.* 65 (1993) 238-41
- 15 EP 0 620 283
JP 11243949
US 5,484,708
US 5,997,817
- 20 US 6,057,120
US 6,103,509
WO 92/07953
WO 99/30152
WO 88/09373

WO 02/34919

PCT/EP01/12148

- 34 -

Patent Claims

1. A mutant of the soluble form of EC 1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH) said mutant characterized in that relative to the corresponding wild-type enzyme and with regard to at least one other selected sugar
5 substrate, it has an at least two-fold increased substrate specificity for glucose.
2. The mutant according to claim 1 further characterized in that said selected sugar is selected from the group consisting of maltose and galactose.
3. The mutant according to claim 1 or 2 further characterized in that said selected sugar is maltose.
- 10 4. The mutant of PQQ-dependent s-GDH according to Claim 1 further characterized in that said substrate specificity for glucose is improved at least 3-fold.
5. The mutant of PQQ-dependent s-GDH according to Claim 1 further characterized in that said substrate specificity for glucose is improved at least 5-fold.
- 15 6. A mutant of the soluble form of EC 1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH) said mutant characterized in that
 - a) the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme, and
 - b) the substrate specific reactivity towards maltose is 30% or less as compared to the wild-type enzyme.
- 20 7. The mutant according to claim 6 further characterized in that said substrate specific reactivity towards maltose is 20% or less as compared to the wild-type enzyme.
8. The mutant of a PQQ-dependent s-GDH according to any of claims 1- 7 further characterized in that the wild-type s-GDH is isolated from a strain of the *Acinetobacter* species group consisting of *A. calcoaceticus* and *A. baumannii*.

WO 02/34919

PCT/EP01/12148

- 35 -

9. A mutant protein of PQQ-dependent s-GDH comprising an amino acid residue substitution at the amino acid position corresponding to position 348 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24).
10. A mutant protein of PQQ-dependent s-GDH comprising at least two amino acid residue substitutions at amino acid positions corresponding to positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 16, 22, 76, 116, 120, 127, 143, 168, 169, 171, 177, 227, 230, 231, 245, 255, 277, 295, 299, 308, 317, 341, 348, 349, 355, 422, 428 and 438, wherein the amino acid residue T348 is replaced.
11. The mutant of claim 10 further characterized in that at amino acid positions corresponding to positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24) the amino acid in position 348 and at least one of the following amino acid residues 16, 116, 120, 127, 169, 171, 177, 227, 255, 277, 299, 317, 355 and 438 are substituted.
12. The mutant protein of claim 10 comprising substitutions of the amino acid residues at positions 348 and 428.
13. A mutant protein of PQQ-dependent s-GDH comprising at least three amino acid residue substitutions at amino acid positions corresponding positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 171, 227, 230, 245, 341, 348, 349, and 428 wherein both the amino acid residues T348 and N428 are substituted.
14. The mutant according to claim 12 or 13 further characterized in that asparagine at position 428 is substituted with an amino acid residue selected from the group consisting of leucine, proline and valine.
15. The mutant according to any of claims 9 to 14 further characterized in that threonine at position 348 is substituted with an amino acid residue selected from the group consisting of alanine, glycine and serine.

WO 02/34919

PCT/EP01/12148

- 36 -

16. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of WPXaaVAPS (SEQ ID NO: 1), wherein said Xaa residue is an amino acid residue other than threonine.
17. The mutant protein of claim 16 further characterized in that said Xaa residue is glycine.
- 5 18. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of TAGXaaVQK (SEQ ID NO: 2), wherein said Xaa residue is an amino acid residue other than asparagine.
19. The mutant protein of claim 18 further characterized in that said Xaa residue is proline.
20. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of
10 ADGXaaNGL (SEQ ID NO: 3), wherein said Xaa residue is an amino acid residue other than glutamine.
21. The mutant of claim 20 further characterized in that said Xaa residue is selected from the group consisting of aspartic acid, glutamic acid, methionine, proline, serine, alanine or glycine.
- 15 22. An isolated polynucleotide encoding the s-GDH mutant protein according to any of claims 9 to 21.
23. An expression vector comprising an isolated polynucleotide as defined in claim 22 operably linked to a promoter sequence capable of promoting the expression of said polynucleotide in a host cell.
- 20 24. A host cell comprising the expression vector of claim 23.
25. A process for producing s-GDH variants comprising culturing the host cell of claim 24 under conditions suitable for production of the enzyme variants.
26. An expression vector comprising an isolated polynucleotide as defined in claim 22 operably linked to a promoter sequence capable of promoting its expression in a cell-
25 free peptide synthesis system.

WO 02/34919

PCT/EP01/12148

- 37 -

27. A process for producing s-GDH variants with the construct of claim 26 in a cell-free peptide synthesis system under conditions suitable for production of the said enzyme variants.
28. A method of detecting, determining or measuring glucose in a sample using a s-GDH
5 mutant according to any of the preceeding claims, said improvement comprising contacting the sample with the mutant.
29. The method of claim 28 further characterized in that said detection, determination or measurement of glucose is performed using a sensor or test strip device.
30. A device for the detection or measurement of glucose in a sample comprising a s-GDH
10 mutant according to any of claims 1- 29 and other reagents required for said measurement.

WO 02/34919

PCT/EP01/12148

1/7

Figure 1: DNA and protein sequence of *A. calcoaceticus* s-GDH
(without signalpeptide)

```
5      1 GATGTTCTCTAACTCCATCTCAATTGCTAAAGCGAAATCAGAGAACTT 50
      |||
      1 AspValProLeuThrProSerGlnPheAlaLysAlaLysSerGluAsnPh 17
10     51 TGACAAGAAAGTTATTCTATCTAATCTAAATAAGCCGACGCGTTGTTAT 100
      |||
      18 eAspLysLysValIleLeuSerAsnLeuAsnLysProHisAlaLeuLeuT 34
15     101 GGGGACCAGATAATCAAATTTGGTTAACTGAGCGAGCAACAGGTAAGATT 150
      |||
      35 rpGlyProAspAsnGlnIleTrpLeuThrGluArgAlaThrGlyLysIle 50
20     151 CTAAGAGTTAATCCAGAGTCGGGTAGTGTAAAAACAGTTTTCAGGTACC 200
      |||
      51 LeuArgValAsnProGluSerGlySerValLysThrValPheGlnValPr 67
25     201 AGAGATTGTCAATGATGCTGATGGGCAGAATGGTTTATTAGGTTTTCCT 250
      |||
      68 oGluIleValAsnAspAlaAspGlyGlnAsnGlyLeuLeuGlyPheAlaP 84
30     251 TCCATCCTGATTTTAAAAATAATCCTTATATCTATATTTTCAGGTACATT 300
      |||
      85 heHisProAspPheLysAsnAsnProTyrIleTyrIleSerGlyThrPhe 100
35     301 AAAAAATCCGAAATCTACAGATAAAGAATTACCGAACCAACGATTATTTCG 350
      |||
      101 LysAsnProLysSerThrAspLysGluLeuProAsnGlnThrIleIleAr 117
40     351 TCGTTATACCTATAATAAATCAACAGATACGCTCGAGAAGCCAGTCGATT 400
      |||
      118 gArgTyrThrTyrAsnLysSerThrAspThrLeuGluLysProValAspL 134
45     401 TATTAGCAGGATTACCTTCATCAAAGACCATCAGTCAGGTCGTCTTGTC 450
      |||
      135 euLeuAlaGlyLeuProSerSerLysAspHisGlnSerGlyArgLeuVal 150
50     451 ATTGGGCCAGATCAAAGATTATTATACGATTGGTGACCAAGGGCGTAA 500
      |||
      151 ileGlyProAspGlnLysIleTyrTyrThrIleGlyAspGlnGlyArgAs 167
55     501 CCAGCTTGCTTATTTGTTCTTGCCAAATCAAGCACACATACGCCAACTC 550
      |||
      168 nGlnLeuAlaTyrLeuPheLeuProAsnGlnAlaGlnHisThrProThrG 184
60     551 AACAAGAAGTGAATGGTAAAGACTATCACACCTATATGGGTAAAGTACTA 600
      |||
      185 lnGlnGluLeuAsnGlyLysAspTyrHisThrTyrMetGlyLysValLeu 200
65     601 CGCTTAAATCTTGATGGAAGTATTCCAAAGGATAATCCAAGTTTAAACGG 650
      |||
      201 ArgLeuAsnLeuAspGlySerIleProLysAspAsnProSerPheAsnGl 217
70     651 GGTGGTTAGCCATATTTATACACTTGGACATCGTAATCCGCAGGGCTTAG 700
      |||
      218 yValValSerHisIleTyrThrLeuGlyHisArgAsnProGlnGlyLeuA 234
75     701 CATTCACTCCAAATGGTAAATTATTGCAGTCTGAACAAGGCCCAAACTCT 750
      |||
      235 laPheThrProAsnGlyLysLeuLeuGlnSerGluGlnGlyProAsnSer 250
```


WO 02/34919

PCT/EP01/12148

2/7

Figure 1: Continued (second and last page)

```

5      751 GACGATGAAATTAACCTCATTGTCAAAGGTGGCAATTATGGTTGGCCGAA 800
      |||||||
251 AspAspGluIleAsnLeuIleValLysGlyGlyAsnTyrGlyTrpProAs 267

801 TGTAGCAGGTTATAAAGATGATAGTGGCTATGCTTATGCAAATTATTCAG 850
      |||||||
10     268 nValAlaGlyTyrLysAspAspSerGlyTyrAlaTyrAlaAsnTyrSerA 284

851 CAGCAGCCAATAAGTCAATTAAAGGATTTAGCTCAAATGGAGTAAAGTA 900
      |||||||
15     285 laAlaAlaAsnLysSerIleLysAspLeuAlaGlnAsnGlyValLysVal 300

901 GCCGCAGGGTCCCTGTGACGAAAGAATCTGAATGGACTGGTAAAACTT 950
      |||||||
20     301 AlaAlaGlyValProValThrLysGluSerGluTrpThrGlyLysAsnPh 317

951 TGTCACCACTTAAAACTTTATATACCGTTCAAGATACCTACAATA 1000
      |||||||
25     318 eValProProLeuLysThrLeuTyrThrValGlnAspThrTyrAsnTyrA 334

1001 ACGATCCAACCTTGTGGAGAGATGACCTACATTTGCTGGCCAACAGTTGCA 1050
      |||||||
25     335 snAspProThrCysGlyGluMetThrTyrIleCysTrpProThrValAla 350

1051 CCGTCATCTGCCTATGTCTATAAGGGCGGTAAAAAGCAATTACTGGTTG 1100
      |||||||
30     351 ProSerSerAlaTyrValTyrLysGlyGlyLysLysAlaIleThrGlyTr 367

1101 GGAAAATACATTATTGGTTCCATCTTTAAACGTTGGTGTCTTTTCCGTA 1150
      |||||||
35     368 pGluAsnThrLeuLeuValProSerLeuLysArgGlyValIlePheArgI 384

1151 TTAAGTTAGATCCAACCTTATAGCACTACTTATGATGACGCTGTACCGATG 1200
      |||||||
40     385 leLysLeuAspProThrTyrSerThrThrTyrAspAspAlaValProMet 400

1201 TTTAAGAGCAACAACCGTTATCGTGATGTGATTGCAAGTCCAGATGGGAA 1250
      |||||||
45     401 PheLysSerAsnAsnArgTyrArgAspValIleAlaSerProAspGlyAs 417

1251 TGTCTTATATGTATTAACTGATACTGCCGAAATGTCCAAAAGATGATG 1300
      |||||||
45     418 nValLeuTyrValLeuThrAspThrAlaGlyAsnValGlnLysAspAspG 434

1301 GCTCAGTAACAAATACATTAGAAAACCCAGGATCTCTCATTAGTTCACC 1350
      |||||||
50     435 lySerValThrAsnThrLeuGluAsnProGlySerLeuIleLysPheThr 450

1351 TATAAGGCTAAG 1362
      |||||||
55     451 TyrLysAlaLys 454

```

WO 02/34919

PCT/EP01/12148

3/7

Figure 2: Amino acid sequences of *A. calcoaceticus* (top) and *A. baumannii* (bottom)

```

5      1 DVPLTPSQFAKAKSENFDDKKVILSNLNKPHALLWGPDNQIWLTERATGKI 50
      |:|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      1 DIPLTPAQFAKAKTENFDDKKVILSNLNKPHALLWGPDNQIWLTERATGKI 50

10     51 LRVNPESGSVKTVFQVPEIVNDADGQNGLLGFAPHPDFKNNPYIYISGTF 100
      ||||| ||| |||||.|||||.|||||.|||||.|||||.|||||.
      51 LRVNPVSGSAKTVFQVPEIVSDADGQNGLLGFAPHPDFKHNPYIYISGTF 100

15     101 KNPKSTDKELPNQTIIRRYTYNKSTDLEKPVDLLAGLPSSKDHQSGRLV 150
      |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      101 KNPKSTDKELPNQTIIRRYTYNKTTDTFEKPIDLIAGLPSSKDHQSGRLV 150

20     151 IGPDKIYYTIGDQGRNQLAYLFLPNQAQHTPTQQELNGKDYHTYMGKVL 200
      |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      151 IGPDKIYYTIGDQGRNQLAYLFLSNQAQHTPTQQELNSKDYHTYMGKVL 200

25     201 RLNLDGSI PKDNPSFNGVVSHIYTLGHRNPQGLAFTPNGKLLQSEQGPNS 250
      |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      201 RLNLDGSI PKDNPSFNGVVSHIYTLGHRNPQGLAFAPNGKLLQSEQGPNS 250

30     251 DDEINLIVKGGNYGWPNAVAGYKDDSGYAYANYSAANKS.IKDLAONGVK 299
      |||||.|||.|||||.|||||.|||||.|||||.|||||.|||||.|||.
      251 DDEINLVKGGNYGWPNAVAGYKDDSGYAYANYSAATNKSQIKDLAONGIK 300

35     300 VAAGVPVTKESEWTGKNFVPPPKTLYTVQDTYNYNDPTCGEMTYICWPTV 349
      || |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      301 VATGVPVTKESEWTGKNFVPPPKTLYTVQDTYNYNDPTCGEMAYICWPTV 350

40     350 APSSAYVYKGGKKAITGWENTLLVPSLKRGVIFRIKLDPTYSTTYDDAVP 399
      |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      351 APSSAYVYTGKKKAIPGWENTLLVPSLKRGVIFRIKLDPTYSTTLDDAIP 400

      400 MFKSNNRYRDVIASPDGNVLYVLTDTAGNVQKDDGSVTNTLENPGSLIKF 449
      |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
      401 MFKSNNRYRDVIASPEGNTLYVLTDTAGNVQKDDGSVHTLENPGSLIKF 450


      450 TYKAK 454
      || |
      451 TYNGK 455
    
```

WO 02/34919

PCT/EP01/12148

4/7

Figure 3: Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)



WO 02/34919

PCT/EP01/12148

5/7

Figure 4: Nucleotide (DNA) sequence of the PACSGDH vector

1 CACTAACTGA TTACGCACCG CATGTAACCG TTTTCAATCT GTGAGTAAAT
5 51 TCACAGTTTA TTAACATTGT GATAGCTATG ATGACAACGT TTGTTCGCACT
101 GTAAC TAACG TGTAACAGTT AGTTGT CAGT TTGCTGGGG TATTTTCGCTT
15 151 ATAAAAACCG TTATCACAAT ATCCCGCGAC TACCGGACAA AAATAAAGAG
201 TTGAATAAGA GCTTATCCCA TTAGGGCTAT TTTACTTGCC ATTTTGGACC
251 TGGGCAGTGC TCGCCAAAAC GCGTTAGCGT TTTGAACGCG CTAGCGGCGG
15 301 CCCGAAGGGC GAGCGTAGCG AGTCAAACCT CACGTACTAC GTGTACGCTC
351 CGGTTTTTGC GCGCTGTCCG TGTCCAACT GCTGCGCCAA TAACGCCTGG
20 401 TGGGATAGGC TCTAAATACG CTTCGGCGTT CAGTAACACG CGTTAACGTG
451 CTGAACAGCC GGGCATTTTT TTACGCTATA CCCTACATAA TAAAACCGGA
501 GCTACCATGA ATAAGAAGGT ACTGACCCTT TCTGCCGTGA TGGCAAGTCT
25 551 GTTATTTCGGC GCGCACGCGC ATGCCGCGA TGTTCTCTA ACTCCATCTC
601 AATTTGCTAA AGCGAAATCA GAGAACTTTG ACAAGAAAGT TATTCATCT
30 651 AATCTAAATA AGCCGCACGC GTTGTATTGG GGACCAGATA ATCAAATTTG
701 GTTAACTGAG CGAGCAACAG GTAAGATTCT AAGAGTTAAT CCAGAGTCGG
751 GTAGTGTAAG AACAGTTTTT CAGGTACCAG AGATTGTCAA TGATGCTGAT
35 801 GGGCAGAATG GTTTATTAGG TTTTGCCCTC CATCCTGATT TTAATAATAA
851 TCCTTATATC TATATTTTCA GTACATTTAA AAATCCGAAA TCTACAGATA
40 901 AAGAATTACC GAACCAAACG ATTATTCGTC GTTATACCTA TAATAAATCA
951 ACAGATACGC TCGAGAAGCC AGTCGATTTA TTAGCAGGAT TACCTTCATC
1001 AAAAGACCAT CAGTCAGGTC GTCTTGTCAT TGGGCCAGAT CAAAAGATTT
45 1051 ATTATACGAT TGGTGACCAA GGGCGTAACC AGCTTGCTTA TTTGTTCTTG
1101 CCAAATCAAG CACAACATAC GCCAACTCAA CAAGAACTGA ATGGTAAAGA
50 1151 CTATCACACC TATATGGGTA AAGTACTACG CTTAAATCTT GATGGAAGTA
1201 TTCCAAAGGA TAATCCAAGT TTTAACGGGG TGGTTAGCCA TATTTATACA
1251 CTTGGACATC GTAATCCGCA GGGCTTAGCA TTCACTCCAA ATGGTAAATT
55 1301 ATTGCAGTCT GAACAAGGCC CAACTCTGA CGATGAAATT AACCTCATTG
1351 TCAAAGGTGG CAATTATGGT TGGCCGAATG TAGCAGGTTA TAAAGATGAT
60 1401 AGTGGCTATG CTTATGCAAA TTATTAGCA GCAGCCAATA AGTCAATTAA
1451 GGATTTAGCT CAAAATGGAG TAAAAGTAGC CGCAGGGGTC CCTGTGACGA
1501 AAGAATCTGA ATGGACTGGT AAAAATTTG TCCCACCATT AAAAATTTA

WO 02/34919

PCT/EP01/12148

6/7

Figure 4: Continued (second out of three pages)

5 1551 TATACCGTTC AAGATACCTA CAACTATAAC GATCCAACCT GTGGAGAGAT
1601 GACCTACATT TGCTGGCCAA CAGTTGCACC GTCATCTGCC TATGTCTATA
1651 AGGGCGGTAA AAAAGCAATT ACTGGTTGGG AAAATACATT ATTGGTTCCA
10 1701 TCTTTAAAC GTGGTGTCTAT TTTCCTATT AAGTTAGATC CAACTTATAG
1751 CACTACTTAT GATGACGCTG TACCGATGTT TAAGAGCAAC AACCGTTATC
1801 GTGATGTGAT TGCAAGTCCA GATGGGAATG TCTTATATGT ATTAAGTATG
15 1851 ACTGCCGGA ATGTCCAAA AGATGATGGC TCAGTAACAA ATACATTAGA
1901 AAACCCAGGA TCTCTCATT AGTTCACCTA TAAGGCTAAG TAATACAGTC
20 1951 GCATTAAAA ACCGATCTAT AAAGATCGGT TTTTITAGTT TTAGAAAAGA
2001 ATTCACTGGC CGTCGTTTTA CAACGTCGTG ACTGGGAAAA CCTTGGCGTT
2051 ACCCAACTTA ATCGCCTTGC AGCACATCCC CCTTTCGCCA GCTGGCGTAA
25 2101 TAGCGAAGAG GCCCGCACCG ATCGCCCTTC CCAACAGTTG CGCAGCCTGA
2151 ATGGCGAATG GCGCCTGATG CGGTATTTTC TCCTTACGCA TCTGTGCGGT
30 2201 ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC
2251 ATAGTTAAGC CAGCCCGAC ACCCGCCAAC ACCCGCTGAC GCGCCCTGAC
2301 GGGCTTGTCT GCTCCCGGCA TCCGCTTACA GACAAGCTGT GACCGTCTCC
35 2351 GGGAGCTGCA TGTGTGAGAG GTTTTCACCG TCATCACCGA AACGCGCGAG
2401 ACGAAAGGGC CTCGTGATAC GCCTATTTTT ATAGGTTAAT GTCATGATAA
40 2451 TAATGGTTTC TTAGACGTCA GGTGGCACTT TTCGGGAAA TGTGCGCGGA
2501 ACCCCTATTT GTTTATTTTT CTAAATACAT TCAAATATGT ATCCGCTCAT
2551 GAGACAATAA CCCTGATAAA TGCTTCAATA ATATTGAAAA AGGAAGAGTA
45 2601 TGAGTATTCA ACATTTCCGT GTCGCCCTTA TTCCCTTTTT TGCGGCATTT
2651 TGCCTTCCTG TTTTGTCTCA CCCAGAAACG CTGGTGAAAG TAAAAGATGC
50 2701 TGAAGATCAG TTGGGTGCAC GAGTGGGTTA CATCGAACTG GATCTCAACA
2751 GCGGTAAGAT CCTTGAGAGT TTTCGCCCCG AAGAACGTTT TCCAATGATG
2801 AGCACTTTTA AAGTTCTGCT ATGTGGGCGG GTATTATCCC GTATTGACGC
55 2851 CGGGCAAGAG CAACTCGGTC GCCGCATACA CTATTCTCAG AATGACTTGG
2901 TTGAGTACTC ACCAGTCACA GAAAAGCATC TTACGGATGG CATGACAGTA
60 2951 AGAGAATTAT GCAGTGCTGC CATAACCATG AGTGATAACA CTGCGGCCAA
3001 CTTACTTCTG ACAACGATCG GAGGACCGAA GGAGCTAACC GCTTTTTTGC
3051 ACAACATGGG GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG

WO 02/34919

PCT/EP01/12148

7/7

Figure 4: Continued (third and last page)

5 3101 AATGAAGCCA TACCAAACGA CGAGCGTGAC ACCACGATGC CTGTAGCAAT
3151 GGCAACAACG TTGCGCAAAC TATTAAGTGG CGAACTACTT ACTCTAGCTT
3201 CCCGGCAACA ATTAATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA
10 3251 CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG
3301 AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG
3351 GTAAGCCCTC CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT
15 3401 ATGGATGAAC GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA
3451 GCATTGGTAA CTGTCAGACC AAGTTTACTC ATATATACTT TAGATTGATT
3501 TAAAACTTCA TTTTAAATTT AAAAGGATCT AGGTGAAGAT CCTTTTGTAT
20 3551 AATCTCATGA CAAAATCCC TTAACGTGAG TTTTCGTTCC ACTGAGCGTC
3601 AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT TTTTCTCTGC
25 3651 GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT
3701 TGTTCGCCGG ATCAAGAGCT ACCAACTCTT TTTCCGAAGG TAACTGGCTT
3751 CAGCAGAGCG CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG
30 3801 GCCACCACTT CAAGAACTCT GTAGCACCGC CTACATACCT CGCTCTGCTA
3851 ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT GTCTTACCGG
35 3901 GTTGGACTCA AGACGATAGT TACCGGATAA GGCAGCGCGG TCGGGCTGAA
3951 CGGGGGGTTT GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA
40 4001 CTGAGATACC TACAGCGTGA GCTATGAGAA AGCGCCACGC TTCCCGAAGG
4051 GAGAAAGGCG GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC
4101 GCACGAGGGA GCTTCCAGGG GGAAACGCCT GGTATCTTTA TAGTCCTGTC
45 4151 GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTGTGAT GTCGTCAGG
4201 GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT TTACGGTTCC
4251 TGGCCTTTTG CTGGCCTTTT GCTCACATGT TCTTCTCTGC GTTATCCCCT
50 4301 GATTCTGTGG ATAACCGTAT TACCGCCTTT GAGTGAGCTG ATACCGCTCG
4351 CCGCAGCCGA ACGACGGGGC CCG

WO 02/34919

PCT/EP01/12148

- 1 -

SEQUENCE LISTING

5 <110> F. Hoffmann-La Roche AG
 Roche Diagnostics GmbH
 <120> New forms of soluble Pyrroloquinoline Quinone-dependent
 Glucose Dehydrogenase
 10 <130> 19139 WO
 <140>
 <141>
 15 <150> EP 00123512.6
 <151> 2000-10-27
 <150> EP 00127294.7
 <151> 2000-12-19
 20 <160> 25
 <170> PatentIn Ver. 2.1
 25 <210> 1
 <211> 7
 <212> PRT
 <213> Acinetobacter calcoaceticus
 <400> 1
 30 Trp Pro Xaa Val Ala Pro Ser
 1 5
 35 <210> 2
 <211> 7
 <212> PRT
 <213> Acinetobacter calcoaceticus
 <400> 2
 40 Thr Ala Gly Xaa Val Gln Lys
 1 5
 45 <210> 3
 <211> 7
 <212> PRT
 <213> Acinetobacter calcoaceticus
 <400> 3
 50 Ala Asp Gly Xaa Asn Gly Leu
 1 5
 55 <210> 4
 <211> 26

WO 02/34919

PCT/EP01/12148

- 2 -

<212> DNA
 <213> Artificial Sequence
 <220>
 5 <223> Description of Artificial Sequence:sense primer
 GF23
 <400> 4
 10 cgcgcacgcg catgccgccg atgttc 26
 <210> 5
 <211> 23
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:antisense
 primer GR23
 20 <400> 5
 gacggccagt gaattctttt cta 23
 <210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence:sense primer
 GDH F2
 <400> 6
 35 ttaacgtgct gaacagccgg 20
 <210> 7
 <211> 20
 40 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:sense primer
 45 GDH F3
 <400> 7
 gatgctgatg ggcagaatgg 20
 50 <210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 55

WO 02/34919

PCT/EP01/12148

- 3 -

<220>
<223> Description of Artificial Sequence:sense primer
GDH F4

5 <400> 8
atatgggtaa agtactacgc 20

<210> 9
10 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
15 <223> Description of Artificial Sequence:sense primer
GDH F5

<400> 9
20 acgatccaac ttgtggagag 20

<210> 10
<211> 20
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisense
primer GDH R1
30

<400> 10
cgattaagtt gggtaacgcc 20

<210> 11
35 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Description of Artificial Sequence:antisense
primer GDH R2

<400> 11
45 atacggaaaa tgacaccacg 20

<210> 12
<211> 20
50 <212> DNA
<213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence:antisense
primer GDH R3

WO 02/34919

PCT/EP01/12148

- 4 -

<400> 12
gggccttggt cagactgcaa 20

5
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Description of Artificial Sequence:antisense
primer GDH R4

15 <400> 13
caagacgacc tgactgatgg 20

20 <210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:antisense
primer GDH R5

30 <400> 14
cataacaacg cgtgcggctt 20

35 <210> 15
<211> 29
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence:sense primer
EGF

45 <400> 15
tccaacttgt ggannnatga cctacattt 29

50 <210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Description of Artificial Sequence:antisense
primer EGR

<400> 16
aaatgtaggt catnnntcca caagttgga 29

WO 02/34919

PCT/EP01/12148

- 5 -

5 <210> 17
 <211> 29
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence:sense primer
 TSF

 <400> 17
 catttgctgg ccannngttg caccgtcat 29

15 <210> 18
 <211> 29
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence:antisense
 primer TSR

25 <400> 18
 atgacggtgc aacnnntggc cagcaaatg 29

30 <210> 19
 <211> 29
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence:sense primer
 NHF

40 <400> 19
 tactggttgg gaannnacat tattggttc 29

45 <210> 20
 <211> 29
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Description of Artificial Sequence:antisense
 primer NHR

 <400> 20
 gaaccaataa tgtnnnttcc caaccagta 29

55 <210> 21

WO 02/34919

PCT/EP01/12148

- 6 -

```

<211> 29
<212> DNA
<213> Artificial Sequence

5 <220>
  <223> Description of Artificial Sequence:sense primer
    SNF

  <400> 21
10 tgatgtgatt gcannnccag atgggaatg 29

  <210> 22
  <211> 29
15 <212> DNA
  <213> Artificial Sequence

  <220>
  <223> Description of Artificial Sequence:antisense
20 primer SNR

  <400> 22
  cattcccatc tggnnntgca atcacatca 29

25

  <210> 23
  <211> 1362
  <212> DNA
  <213> Acinetobacter calcoaceticus
30

  <220>
  <221> CDS
  <222> (1)..(1362)

35 <400> 23
  gat gtt cct cta act cca tct caa ttt gct aaa gcg aaa tca gag aac 48
  Asp Val Pro Leu Thr Pro Ser Gln Phe Ala Lys Ala Lys Ser Glu Asn
    1 5 10 15

40 ttt gac aag aaa gtt att cta tct aat cta aat aag ccg cac gcg ttg 96
  Phe Asp Lys Lys Val Ile Leu Ser Asn Leu Asn Lys Pro His Ala Leu
    20 25 30

  tta tgg gga cca gat aat caa att tgg tta act gag cga gca aca ggt 144
45 Leu Trp Gly Pro Asp Asn Gln Ile Trp Leu Thr Glu Arg Ala Thr Gly
    35 40 45

  aag att cta aga gtt aat cca gag tgc ggt agt gta aaa aca gtt ttt 192
50 Lys Ile Leu Arg Val Asn Pro Glu Ser Gly Ser Val Lys Thr Val Phe
    50 55 60

  cag gta cca gag att gtc aat gat gct gat ggg cag aat ggt tta tta 240
  Gln Val Pro Glu Ile Val Asn Asp Ala Asp Gly Gln Asn Gly Leu Leu
    65 70 75 80
55

```

WO 02/34919

PCT/EP01/12148

- 7 -

	ggt ttt gcc ttc cat cct gat ttt aaa aat aat cct tat atc tat att	288
	Gly Phe Ala Phe His Pro Asp Phe Lys Asn Asn Pro Tyr Ile Tyr Ile	
	85 90 95	
5	tca ggt aca ttt aaa aat ccg aaa tct aca gat aaa gaa tta ccg aac	336
	Ser Gly Thr Phe Lys Asn Pro Lys Ser Thr Asp Lys Glu Leu Pro Asn	
	100 105 110	
10	caa acg att att cgt cgt tat acc tat aat aaa tca aca gat acg ctc	384
	Gln Thr Ile Ile Arg Arg Tyr Thr Tyr Asn Lys Ser Thr Asp Thr Leu	
	115 120 125	
15	gag aag cca gtc gat tta tta gca gga tta cct tca tca aaa gac cat	432
	Glu Lys Pro Val Asp Leu Leu Ala Gly Leu Pro Ser Ser Lys Asp His	
	130 135 140	
20	cag tca ggt cgt ctt gtc att ggg cca gat caa aag att tat tat acg	480
	Gln Ser Gly Arg Leu Val Ile Gly Pro Asp Gln Lys Ile Tyr Tyr Thr	
	145 150 155 160	
25	att ggt gac caa ggg cgt aac cag ctt gct tat ttg ttc ttg cca aat	528
	Ile Gly Asp Gln Gly Arg Asn Gln Leu Ala Tyr Leu Phe Leu Pro Asn	
	165 170 175	
30	caa gca caa cat acg cca act caa caa gaa ctg aat ggt aaa gac tat	576
	Gln Ala Gln His Thr Pro Thr Gln Gln Glu Leu Asn Gly Lys Asp Tyr	
	180 185 190	
35	cac acc tat atg ggt aaa gta cta cgc tta aat ctt gat gga agt att	624
	His Thr Tyr Met Gly Lys Val Leu Arg Leu Asn Leu Asp Gly Ser Ile	
	195 200 205	
40	cca aag gat aat cca agt ttt aac ggg gtg gtt agc cat att tat aca	672
	Pro Lys Asp Asn Pro Ser Phe Asn Gly Val Val Ser His Ile Tyr Thr	
	210 215 220	
45	ctt gga cat cgt aat ccg cag ggc tta gca ttc act cca aat ggt aaa	720
	Leu Gly His Arg Asn Pro Gln Gly Leu Ala Phe Thr Pro Asn Gly Lys	
	225 230 235 240	
50	tta ttg cag tct gaa caa ggc cca aac tct gac gat gaa att aac ctc	768
	Leu Leu Gln Ser Glu Gln Gly Pro Asn Ser Asp Asp Glu Ile Asn Leu	
	245 250 255	
55	att gtc aaa ggt ggc aat tat ggt tgg ccg aat gta gca ggt tat aaa	816
	Ile Val Lys Gly Gly Asn Tyr Gly Trp Pro Asn Val Ala Gly Tyr Lys	
	260 265 270	
60	gat gat agt ggc tat gct tat gca aat tat tca gca gca gcc aat aag	864
	Asp Asp Ser Gly Tyr Ala Tyr Ala Asn Tyr Ser Ala Ala Ala Asn Lys	
	275 280 285	
65	tca att aag gat tta gct caa aat gga gta aaa gta gcc gca ggg gtc	912
	Ser Ile Lys Asp Leu Ala Gln Asn Gly Val Lys Val Ala Ala Gly Val	
	290 295 300	

WO 02/34919

PCT/EP01/12148

- 8 -

```

      cct gtg acg aaa gaa tct gaa tgg act ggt aaa aac ttt gtc cca cca   960
      Pro Val Thr Lys Glu Ser Glu Trp Thr Gly Lys Asn Phe Val Pro Pro
      305                310                315                320
5
      tta aaa act tta tat acc gtt caa gat acc tac aac tat aac gat cca   1008
      Leu Lys Thr Leu Tyr Thr Val Gln Asp Thr Tyr Asn Tyr Asn Asp Pro
                325                330                335

10  act tgt gga gag atg acc tac att tgc tgg cca aca gtt gca ccg tca   1056
      Thr Cys Gly Glu Met Thr Tyr Ile Cys Trp Pro Thr Val Ala Pro Ser
                340                345                350

      tct gcc tat gtc tat aag ggc ggt aaa aaa gca att act ggt tgg gaa   1104
15  Ser Ala Tyr Val Tyr Lys Gly Gly Lys Lys Ala Ile Thr Gly Trp Glu
                355                360                365

      aat aca tta ttg gtt cca tct tta aaa cgt ggt gtc att ttc cgt att   1152
20  Asn Thr Leu Leu Val Pro Ser Leu Lys Arg Gly Val Ile Phe Arg Ile
                370                375                380

      aag tta gat cca act tat agc act act tat gat gac gct gta ccg atg   1200
      Lys Leu Asp Pro Thr Tyr Ser Thr Thr Tyr Asp Asp Ala Val Pro Met
      385                390                395                400
25

      ttt aag agc aac aac cgt tat cgt gat gtg att gca agt cca gat ggg   1248
      Phe Lys Ser Asn Asn Arg Tyr Arg Asp Val Ile Ala Ser Pro Asp Gly
                405                410                415

30  aat gtc tta tat gta tta act gat act gcc gga aat gtc caa aaa gat   1296
      Asn Val Leu Tyr Val Leu Thr Asp Thr Ala Gly Asn Val Gln Lys Asp
                420                425                430

      gat ggc tca gta aca aat aca tta gaa aac cca gga tct ctc att aag   1344
35  Asp Gly Ser Val Thr Asn Thr Leu Glu Asn Pro Gly Ser Leu Ile Lys
                435                440                445

      ttc acc tat aag gct aag                                           1362
40  Phe Thr Tyr Lys Ala Lys
      450

<210> 24
<211> 454
45 <212> PRT
    <213> Acinetobacter calcoaceticus

<400> 24
50 Asp Val Pro Leu Thr Pro Ser Gln Phe Ala Lys Ala Lys Ser Glu Asn
      1                5                10                15

      Phe Asp Lys Lys Val Ile Leu Ser Asn Leu Asn Lys Pro His Ala Leu
                20                25                30

55  Leu Trp Gly Pro Asp Asn Gln Ile Trp Leu Thr Glu Arg Ala Thr Gly

```

WO 02/34919

PCT/EP01/12148

- 9 -

	35		40		45
	Lys Ile Leu Arg Val Asn Pro Glu Ser Gly Ser Val Lys Thr Val Phe				
	50		55		60
5	Gln Val Pro Glu Ile Val Asn Asp Ala Asp Gly Gln Asn Gly Leu Leu				
	65		70		75 80
	Gly Phe Ala Phe His Pro Asp Phe Lys Asn Asn Pro Tyr Ile Tyr Ile				
10		85		90	95
	Ser Gly Thr Phe Lys Asn Pro Lys Ser Thr Asp Lys Glu Leu Pro Asn				
		100		105	110
15	Gln Thr Ile Ile Arg Arg Tyr Thr Tyr Asn Lys Ser Thr Asp Thr Leu				
		115		120	125
	Glu Lys Pro Val Asp Leu Leu Ala Gly Leu Pro Ser Ser Lys Asp His				
20		130		135	140
	Gln Ser Gly Arg Leu Val Ile Gly Pro Asp Gln Lys Ile Tyr Tyr Thr				
		145		150	155 160
	Ile Gly Asp Gln Gly Arg Asn Gln Leu Ala Tyr Leu Phe Leu Pro Asn				
25		165		170	175
	Gln Ala Gln His Thr Pro Thr Gln Gln Glu Leu Asn Gly Lys Asp Tyr				
		180		185	190
30	His Thr Tyr Met Gly Lys Val Leu Arg Leu Asn Leu Asp Gly Ser Ile				
		195		200	205
	Pro Lys Asp Asn Pro Ser Phe Asn Gly Val Val Ser His Ile Tyr Thr				
		210		215	220
35	Leu Gly His Arg Asn Pro Gln Gly Leu Ala Phe Thr Pro Asn Gly Lys				
		225		230	235 240
	Leu Leu Gln Ser Glu Gln Gly Pro Asn Ser Asp Asp Glu Ile Asn Leu				
40		245		250	255
	Ile Val Lys Gly Gly Asn Tyr Gly Trp Pro Asn Val Ala Gly Tyr Lys				
		260		265	270
45	Asp Asp Ser Gly Tyr Ala Tyr Ala Asn Tyr Ser Ala Ala Ala Asn Lys				
		275		280	285
	Ser Ile Lys Asp Leu Ala Gln Asn Gly Val Lys Val Ala Ala Gly Val				
		290		295	300
50	Pro Val Thr Lys Glu Ser Glu Trp Thr Gly Lys Asn Phe Val Pro Pro				
		305		310	315 320
	Leu Lys Thr Leu Tyr Thr Val Gln Asp Thr Tyr Asn Tyr Asn Asp Pro				
55		325		330	335

WO 02/34919

PCT/EP01/12148

- 10 -

Thr Cys Gly Glu Met Thr Tyr Ile Cys Trp Pro Thr Val Ala Pro Ser
340 345 350

5 Ser Ala Tyr Val Tyr Lys Gly Gly Lys Lys Ala Ile Thr Gly Trp Glu
355 360 365

Asn Thr Leu Leu Val Pro Ser Leu Lys Arg Gly Val Ile Phe Arg Ile
370 375 380

10 Lys Leu Asp Pro Thr Tyr Ser Thr Thr Tyr Asp Asp Ala Val Pro Met
385 390 395 400

Phe Lys Ser Asn Asn Arg Tyr Arg Asp Val Ile Ala Ser Pro Asp Gly
15 405 410 415

Asn Val Leu Tyr Val Leu Thr Asp Thr Ala Gly Asn Val Gln Lys Asp
420 425 430

20 Asp Gly Ser Val Thr Asn Thr Leu Glu Asn Pro Gly Ser Leu Ile Lys
435 440 445

Phe Thr Tyr Lys Ala Lys
450

25

<210> 25
<211> 4373
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:vector pACSGDH

35

<400> 25
cactaactga ttacgcaccg catgtaaccg ttttcaatct gtgagtaaatt tcacagttta 60
ttaacattgt gatagctatg atgacaacgt ttgtcgcaact gtaactaacg tgtaacagtt 120
agttgtcagt ttgtctgggg tatttcgctt ataaaaaccg ttatcacaat atcccgcgac 180
40 taccggacaa aaataaagag ttgaataaga gcttatccca ttagggctat tttacttgcc 240
atthttggacc tgggcagtcg tcgccaaaac gcgttagcgt tttgaacgcg ctacgaggcg 300
cccgaagggc gagcgtagcg agtcaaacct cacgtactac gtgtacgctc cggttttttgc 360
gcgctgtccg tgtccaaaact gctgcgcaa taacgcctgg tgggatagge tctaaatacg 420
cttcggcggt cagtaacacg cgttaacgtg ctgaacagcc gggcattttt ttacgctata 480
45 ccctacataa taaaaccgga gctaccatga ataagaagg actgaccctt tctgcogtga 540
tggaagtct gttattcgcc gcgcacgcgc atgcgcgca tgttcctcta actccatctc 600
aatttgctaa agcgaaatca gagaactttg acaagaaagt tattctatct aatctaaata 660
agccgcacgc gttgttatgg ggaccagata atcaaatttg gttactgag cgagcaacag 720
gtaagattct aagagttaat ccagagtcgg gtagtgtaaa aacagttttt caggtaccag 780
50 agattgtcaa tgatgctgat gggcagaatg gtttattagg ttttgccttc catcctgatt 840
ttaaaaaataa tctttatatac tatatttcag gtacatttaa aaatccgaaa tctacagata 900
aagaattacc gaaccaaaccg attattcgtc gttataccta taataaatca acagatacgc 960
tcgagaagcc agtcgattta ttagcaggat taccttcatac aaaagaccat cagtcaggctc 1020
gtcttgtcat tgggccagat caaaagattt attatacgat tggtgaccaa gggcgtaacc 1080
55 agcttgctta tttgttcttg ccaaatcaag cacaacatac gccaaactcaa caagaactga 1140

WO 02/34919

PCT/EP01/12148

- 11 -

	atggtaaaga	ctatcacacc	tatatgggta	aagtactacg	cttaaactctt	gatggaagta	1200
	ttccaaagga	taatccaagt	tttaacgggg	tggttagcca	tatttataca	cttggacatc	1260
	gtaatccgca	gggettagca	ttcactccaa	atggtaaatt	attgcagtct	gaacaaggcc	1320
	caaactctga	cgatgaaatt	aacctcattg	tcaaagggtg	caattatggg	tgcccgaaatg	1380
5	tagcaggtta	taaagatgat	agtggctatg	cttatgcaaa	ttattcagca	gcagccaata	1440
	agtcaattaa	ggatttagct	caaaatggag	taaaagtagc	cgcaggggtc	cctgtgacga	1500
	aagaatctga	atggactggg	aaaaactttg	tcccaccatt	aaaaacttta	tataccgttc	1560
	aagataccta	caactataac	gatccaactt	gtggagagat	gacctacatt	tgctggccaa	1620
	cagttgcacc	gtcatctgcc	tatgtctata	agggcggtaa	aaaagcaatt	actggttggg	1680
10	aaaatacatt	attggttcca	tctttaaaac	gtggtgtcat	tttccgtatt	aagttagatc	1740
	caacttatag	cactacttat	gatgacgtcg	taccgatgtt	taagagcaac	aaccgttatc	1800
	gtgatgtgat	tgcaagtcca	gatgggaatg	tcttatatgt	attaactgat	actgcoggaa	1860
	atgtccaaaa	agatgatggc	tcagtaacaa	atacattaga	aaaccagga	tctctcatta	1920
	agttcaccta	taaggctaag	taatacagtc	gcattaaaaa	accgatctat	aaagatcggg	1980
15	tttttttagtt	ttagaaaaga	attcactggc	cgtcgtttta	caacgtcgtg	actgggaaaa	2040
	ccctggcggt	acccaactta	atcgccctgc	agcacatccc	cctttcgcca	gctggcgtaa	2100
	tagcgaagag	gcccgcaccg	atcgcccttc	ccaacagttg	cgcagcctga	atggcgaatg	2160
	gcgcctgatg	cggtattttc	tccctacgca	tctgtgcggg	atttcacacc	gcatactggg	2220
	cactctcagt	acaatctgct	ctgatgcgcg	atagttaagc	cagccccgac	acccgccaac	2280
20	acccgctgac	gcgccctgac	gggcttgtct	gctcccggca	tccgcttaca	gacaagctgt	2340
	gaccgtctcc	gggagctgca	tgtgtcagag	gttttcaccg	tcatacccca	aacgcgcgag	2400
	acgaaagggc	ctcgtgatac	gcctattttt	ataggttaat	gtcatgataa	taatggtttc	2460
	ttagacgtca	ggtggcactt	ttcggggaaa	tgtgcgcgga	acccctatct	gtttattttt	2520
	ctaaatacat	tcaaataatgt	atccgctcat	gagacaataa	ccctgataaa	tgcttcaata	2580
25	atattgaaaa	aggaagagta	tgagtattca	acatttccgt	gtcgccctta	ttcccttttt	2640
	tgccgcatct	tgcccttctg	tttttgctca	cccagaaacg	ctgggtgaaag	taaaagatgc	2700
	tgaagatcag	ttgggtgcac	gagtggttta	cctcgaactg	gatctcaaca	gcggtgaagt	2760
	ccttgagatg	tttcgcccgc	aagaacgttt	tccaatgatg	agcactttta	aagttctgtc	2820
	atgtggcgcg	gtatttatccc	gtattgacgc	cgggcaagag	caactcgggc	gccgcataca	2880
30	ctattctcag	aatgacttgg	ttgagtactc	accagtcaca	gaaaagcatc	ttacgggatg	2940
	catgacagta	agagaattat	gcagtgtctg	cataaccatg	agtataaaca	ctgcggccaa	3000
	cttacttctg	acaacgatcg	gaggaccgaa	ggagctaacc	gcttttttgc	acaacatggg	3060
	ggatcatgta	actcgccttg	atcgttggga	acoggagctg	aatgaagcca	taccaaacga	3120
	cgagcgtgac	accacgatgc	ctgtagcaat	ggcaacaacg	ttgcgcaaac	tattaactgg	3180
35	cgaactactt	actctagctt	cccggcaaca	attaatagac	tggtatggagg	cggataaagt	3240
	tgacaggacca	cttctgcgct	cggcccttcc	ggctggctgg	tttattgtctg	ataaatctgg	3300
	agccggtgag	cgtgggtctc	gcgggtatcat	tgacgactg	gggccagatg	gtaagccctc	3360
	ccgtatcgta	gttatctaca	cgaacgggag	tcaggcaact	atggatgaac	gaaatagaca	3420
	gatcgtgtag	ataggtgcct	cactgattaa	gcatttggtta	ctgtcagacc	aagtttactc	3480
40	atatatactt	tagattgatt	taaaacttca	tttttaattt	aaaaggatct	aggtgaagat	3540
	cctttttgat	aatctcatga	ccaaaatccc	ttaacgtgag	ttttcgttcc	actgagcgtc	3600
	agaccccgta	gaaaagatca	aaggatcttc	ttgagatcct	ttttttctgc	gcgtaatctg	3660
	ctgcttgcaa	acaaaaaaac	caccgctacc	agccgttggtt	tgtttgccgg	atcaagagct	3720
	accaactctt	tttccgaagg	taactggctt	cagcagagcg	cagataccaa	atactgtcct	3780
45	tctagtgtag	ccgtagttag	gccaccactt	caagaactct	gtagcaccgc	ctacatacct	3840
	cgtctgtcta	atcctgttac	cagtggctgc	tgccagtggc	gataagtcgt	gtcttacogg	3900
	gttggaactca	agacgatagt	taccggataa	ggcgcagcgg	tcgggctgaa	cgggggggtc	3960
	gtgcacacag	cccagcttgg	agcgaacgac	ctacaccgaa	ctgagatacc	tacagcgtga	4020
	gctatgagaa	agcggcacgc	ttcccgaagg	gagaaaggcg	gacaggtatc	cggtaagcgg	4080
50	cagggtcgga	acaggagagc	gcacgagggg	gcttccaggg	ggaaaacgct	ggtatcttta	4140
	tagtctctgtc	gggttttcgcc	acctctgact	tgagcgtcga	tttttgtgat	gctcgtcagg	4200
	ggggcgagac	ctatggaaaa	acggcagcaa	cggcgccctt	ttacggttcc	tgcccttttg	4260
	ctggcccttt	gctcacatgt	tctttcctgc	gttatcccct	gattctgtgg	ataacogtat	4320
55	taccgccttt	gagtgagctg	ataccgctcg	ccgcagccga	acgacggggc	ccg	4373

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/53 C12N9/04 C12Q1/32 C12Q1/54 //(C12N9/04, C12R1:01)		International Application No PC1, EP 01/12148
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IGARASHI SATOSHI ET AL: "Construction and characterization of mutant water-soluble PQQ glucose dehydrogenases with altered Km values-Site-directed mutagenesis studies on the putative active site." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 264, no. 3, 2 November 1999 (1999-11-02), pages 820-824, XP000990137 ISSN: 0006-291X cited in the application abstract; tables 1,2 --- -/--	1-4, 6-8, 28-30
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 18 March 2002		Date of mailing of the international search report 25/03/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Espen, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12148

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE WPI Section Ch, Week 200066 Derwent Publications Ltd., London, GB; Class B04, AN 2000-679762 XP002168297 & WO 00 66744 A (SODE K), 9 November 2000 (2000-11-09) abstract -& EP 1 176 202 A (SODE K) 30 January 2002 (2002-01-30) tables 3,4</p> <p>---</p>	1-4,6-8, 28-30 =
A	<p>DATABASE WPI Section Ch, Week 200064 Derwent Publications Ltd., London, GB; Class B04, AN 2000-665126 XP002168296 & WO 00 61730 A (SODE K), 19 October 2000 (2000-10-19) abstract</p> <p>---</p>	
A	<p>CLETON-JANSEN A-M ET AL: "CLONING, CHARACTERIZATION AND DNA SEQUENCING OF THE GENE ENCODING THE MR 50000 QUINOPROTEIN GLUCOSE DEHYDROGENASE FROM ACINETOBACTER CALCOACETICUS" MOLECULAR AND GENERAL GENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 217, no. 2/03, June 1989 (1989-06), pages 430-436, XP000990490 ISSN: 0026-8925</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/12148

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0066744	A	09-11-2000	JP	2000312588 A	14-11-2000
			JP	2001197888 A	24-07-2001
			EP	1176202 A1	30-01-2002
			WO	0066744 A1	09-11-2000
WO 0061730	A	19-10-2000	JP	2000350588 A	19-12-2000
			EP	1167519 A1	02-01-2002
			WO	0061730 A1	19-10-2000